



Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

6-8-2010

High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same

Chang-Guo Zhan University of Kentucky, zhan@uky.edu

Hoon Cho University of Kentucky

Hsin-Hsiung Tai University of Kentucky, htai1@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the <u>Pharmacy and Pharmaceutical Sciences Commons</u>

Recommended Citation

Zhan, Chang-Guo; Cho, Hoon; and Tai, Hsin-Hsiung, "High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same" (2010). *Pharmaceutical Sciences Faculty Patents*. 49. https://uknowledge.uky.edu/ps_patents/49

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.



(12) United States Patent

Zhan et al.

(54) HIGH-ACTIVITY MUTANTS OF **BUTYRYLCHOLINESTERASE FOR** COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

- (75) Inventors: Chang-Guo Zhan, Lexington, KY (US); Hoon Cho, Lexington, KY (US); Hsin-Hsiung Tai, Lexington, KY (US)
- (73)Assignee: University of Kentucky Research Foundation, Lexington, KY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 130 days.
- (21)Appl. No.: 12/192,394
- (22) Filed: Aug. 15, 2008

Related U.S. Application Data

- (62) Division of application No. 11/243,111, filed on Oct. 4, 2005, now Pat. No. 7,438,904.
- (51) Int. Cl. A61K 38/46 (2006.01)C12N 9/16 (2006.01)
- (52) U.S. Cl. 424/94.6; 435/196; 435/197
- (58) Field of Classification Search 424/94.6; 435/196, 197

See application file for complete search history.

(56)**References** Cited

U.S. PATENT DOCUMENTS

7,049,121	B2	5/2006	Watkins et al.
2003/0153062	A1	8/2003	Watkins et al.
2004/0120939	A1	6/2004	Watkins et al.

OTHER PUBLICATIONS

Gao, et al.; Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases; Phys. Chem. B; 2005; 109; pp. 23070-23076.

Gao, et al; Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation; Angew. Chem. Int. Ed.; 2006; 45; pp. 653-657.

US 7,731,957 B1 (10) Patent No.: (45) Date of Patent: Jun. 8, 2010

Gao, et al; Modeling evolution of hydrogen bonding and stablization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase; Proteins; 2006; 62; pp. 99-110.

Hamza, et al.; Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants; J. Phys. Chem. B.; 2005; 109; pp. 4776-4782.

Pan, et al.; Computational redesign of human butyrylcholinesterase for anti-cocaine medication; G. Proc. Natl. Acad. Sci. USA; 2005; 102; pp. 16656-16661.

Zhan, et al.; Fundamental reaction mechanism for cocaine metabolism in human butyrylcholinesterase; J. Am. Chem. Soc.; 2003; 125; pp. 2462-2474.

Zhan, et al.; Catalytic Mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine; Biophysical Journal; 2005; 89; pp. 3863-3872.

Xie, et al.; An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient; Moleculare Pharm; 1999; 55; pp. 83-91.

Primary Examiner-Tekchand Saidha

(74) Attorney, Agent, or Firm-Stites & Harbison PLLC; Mandy Wilson Decker; Stephen Weyer

(57)ABSTRACT

A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/ Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/ A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (-)-cocaine compared with wild-type BChE.

5 Claims, 6 Drawing Sheets





(A) BChE-(-)-cocaine non-prereactive complex



(B) BChE-(-)-cocaine prereactive complex



(C) BChE-(+)-cocaine non-prereactive complex



(D) BChE-(+)-cocaine prereactive complex



(A)

(B)









HIGH-ACTIVITY MUTANTS OF BUTYRYLCHOLINESTERASE FOR COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

This application is a division of and claims benefit to U.S. patent application Ser. No. 11/243,111, now allowed, filed Oct. 4, 2005 now U.S. Pat. No. 7,438,904. The contents of which are incorporated herein by reference in their entirety. 10

GOVERNMENT SUPPORT CLAUSE

Subject matter described herein was made with government support under Grant Number R01DA013930 awarded by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The government has certain rights in the described subject matter.

FIELD OF THE INVENTION

The present invention relates to butyrylcholinesterase variant polypeptides, and in particular, butyrylcholinesterase mutants having amino acid substitutions.

BACKGROUND OF THE INVENTION

Cocaine abuse is a major medical and public health problem that continues to defy treatment. The disastrous medical and social consequences of cocaine addiction, such as violent crime, loss in individual productivity, illness and death, have made the development of an effective pharmacological treatment a high priority. However, cocaine mediates its reinforcing and toxic effects by blocking neurotransmitter reuptake and the classical pharmacodynamic approach has failed to yield small-molecule receptor antagonists due to the difficulties inherent in blocking a blocker. An alternative to receptorbased approaches is to interfere with the delivery of cocaine to its receptors and accelerate its metabolism in the body.

The dominant pathway for cocaine metabolism in primates 45 is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the benzoyl ester group (Scheme 1).







Scheme 1. Schematic representation of BChE-catalyzed hydrolysis at the benzoyl ester group.

Only 5% of the cocaine is deactivated through oxidation by the liver microsomal cytochrome P450 system. Cocaine hydrolysis at benzoyl ester group yields ecgonine methyl ester, whereas the oxidation produces norcocaine. The metabolite ecgonine methyl ester is a biologically inactive metabolite, whereas the metabolite norcocaine is hepatotoxic and a local anesthetic. BChE is synthesized in the liver and widely distributed in the body, including plasma, brain, and lung. Extensive experimental studies in animals and humans demonstrate that enhancement of BChE activity by administration of exogenous enzyme substantially decreases cocaine half-life.

Enhancement of cocaine metabolism by administration of BChE has been recognized to be a promising pharmacoki-55 netic approach for treatment of cocaine abuse and dependence. However, the catalytic activity of this plasma enzyme is three orders-of-magnitude lower against the naturally occurring (-)-cocaine than that against the biologically inactive (+)-cocaine enantiomer. (+)-cocaine can be cleared from plasma in seconds and prior to partitioning into the central 60 nervous system (CNS), whereas (-)-cocaine has a plasma half-life of approximately 45-90 minutes, long enough for manifestation of the CNS effects which peak in minutes. Hence, BChE mutants with high activity against (-)-cocaine 65 are highly desired for use in humans. Although some BChE mutants with increased catalytic activity over wild-type BChE have previously been generated, there exists a need for

mutant BChE with even higher catalytic activity. Thus, prior mutants provide limited enhancement in catalytic activity over wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, O. 5 Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duy- 10 sen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J. Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner, 15 G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261; (g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.; Brimijoin, S.; Pang, Y.-P. J. Biol. Chem. 2001, 276, 9330, (h) Sun, H.; Shen, M. L.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. J. Pharmacol. Exp. Ther. 2002, 302, 710, (i) Sun, H.; Pang, Y. 20 P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62, 220 (hereinafter "Sun et al"); and (j) Zhan, C.-G.; Zheng, F.; Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter "Zhan et al"), herein all incorporated by reference, suggested that, for both (-)-cocaine and (+)-cocaine, the BChE-sub- 25 strate binding involves two different types of complexes: non-prereactive and prereactive BChE-substrate complexes. Whereas the non-prereactive BChE-cocaine complexes were first reported by Sun et al. Zhan et al were the first reporting the prereactive BChE-cocaine complexes and reaction coor- 30 dinate calculations, disclosed in Zhan et al.

It was demonstrated that (-)/(+)-cocaine first slides down the substrate-binding gorge to bind to W82 and stands vertically in the gorge between D70 and W82 (non-prereactive complex) and then rotates to a position in the catalytic site 35 within a favorable distance for nucleophilic attack and hydrolysis by S198 (prereactive complex). In the prereactive complex, cocaine lies horizontally at the bottom of the gorge. The main structural difference between the BChE-(-)-cocaine complexes and the corresponding BChE-(+)-cocaine 40 complexes exists in the relative position of the cocaine methyl ester group. Reaction coordinate calculations revealed that the rate-determining step of BChE-catalyzed hydrolysis of (+)-cocaine is the chemical reaction process, whereas for (-)-cocaine the change from the non-prereactive complex to 45 the prereactive complex is rate determining. A further analysis of the structural changes from the non-prereactive complex to the prereactive complex reveals specific amino acid residues hindering the structural changes, providing initial clues for the rational design of BChE mutants with improved 50 catalytic activity for (-)-cocaine.

Previous molecular dynamics (MD) simulations of prereactive BChE-cocaine binding were limited to wild-type BChE. Even for the non-prereactive BChE-cocaine complex, only one mutant (A328W/Y332A) BChE binding with (-)- 55 cocaine was simulated and its catalytic activity for (-)-cocaine was reported by Sun et al. No MD simulation was performed on any prereactive enzyme-substrate complex for (-)- or (+)-cocaine binding with a mutant BChE. In addition, all previous computational studies of Sun et al and Zhan et al 60 of BChE interacting with cocaine were performed based on a homology model of BChE when three-dimensional (3D) X-ray crystal structure was not available for BChE, as taught by Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. J. Biol. Chem. 2003, 278, 41141 (hereinafter 65 "Nicolet et al"), recently reported 3D X-ray crystal structures of BChE. As expected, the structure of BChE is similar to a

previously published theoretical model of this enzyme and to the structure of acetylcholinesterase.

The main difference between the experimentally determined BChE structure and its model was found at the acyl binding pocket (acyl loop) that is significantly bigger than expected. It is unclear whether the structural difference at the acyl binding pocket significantly affect BChE binding with (–)-cocaine and (+)-cocaine. Although previous MD simulations of cocaine binding with wild-type BChE and the reaction coordinate calculations point to some amino acid residues that might need to be mutated for the purpose of improving the catalytic activity for (–)-cocaine hydrolysis, it remained unknown which exact amino acid mutations will result in a BChE with a higher catalytic activity for (–)cocaine.

Computational studies of wild-type BChE and cocaine from Sun, et al, based on a "homology model," suggest that the rate-determining step for BChE-catalyzed hydrolysis of cocaine is the rotation of the cocaine in the active site of BChE. By decreasing the hindrance of the rotation, the rate of the hydrolysis may be enhanced. Sun, et al describes creating an A328W/Y332A BChE mutant by: (1) replacing Tyr332 with Ala, "to reduce the steric hindrance and the π - π interaction that impede rotation," and (2) replacing Ala328 with Trp "to provide a cation- π interaction to restore substrate affinity lost in disabling the π - π interaction."

Sun et al studied the A328W/Y332A BChE mutant using enzyme assays and kinetics. In vitro studies were conducted using human plasma and in vivo studies were conducted using male Sprague-Dawley rats. The mutant was found to have enhanced catalytic properties. The mutant was further studied using molecular modeling. The three dimensional (3D) structure of A328W/Y332A was generated from the computationally generated 3D model of wild-type BChE and changing the relevant residues using commercially available software. Cocaine was docked to the catalytic gorge of the mutant BChE using other commercially available software. The cocaine-enzyme complex was refined by molecular dynamic simulation. The data generated by the molecular modeling studies were consistent with enzyme assays and kinetic data.

It should be noted that all prior computational techniques (molecular docking and molecular dynamics simulation) used by other researchers are based on an empirical force field which cannot be used to perform any necessary reaction coordinate calculation for the detailed understanding of the complicated catalytic reaction process. As it is well-known, it is particularly challenging to model and simulate the detailed reaction pathway and predict the kinetics of such an enzymatic reaction.

U.S. Patent Application Publication Nos. 2004/0121970; 2004/0120939; and 2003/0153062, describe 20+BChE mutants, or "variants," from human and other animals, each having from one to six amino acid alterations and increased cocaine hydrolysis activity. For example, mutants include F227A/A328W; F227A/S287G/A328W; A119S/S287G/ A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/ 287G/A328W and A119S/F227A/S287G/A328W/Y332M. The mutants have varying increases in catalytic activity, up to 100-fold increase relative to wild-type BChE.

25

40

There exists a need in the art for determining which proposed mutant BChEs should have ever increasing catalytic activity and for generating those mutants which should have enhanced catalytic activity.

SUMMARY OF THE INVENTION

The present invention includes five novel human BChE mutants that have unexpected increased catalytic efficiency for cocaine hydrolysis. The mutants have various unique amino acid residue substitutions which provide the surprising enhanced catalytic activity. These mutants are (1) a 1998/ A328W/Y332G mutant (SEQ ID NO: 2), which has a approximately 65-fold improved catalytic efficiency against (-)-cocaine; (2) a 199S/F227A/A328W/Y332G mutant 15 (SEQ ID NO: 8), which has an approximately 148-fold improved catalytic efficiency against (-)-cocaine; (3) a 1998/ S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has an approximately 456-fold improved catalytic efficiency against (-)-cocaine; a 1998/F227A/S287G/A328W/Y332G 20 mutant (SEQ ID NO: 20), which has an approximately 1,003fold improved catalytic efficiency against (-)-cocaine; and a 199S/F227A/S287G/A328W/E441D mutant (SEQ ID NO: 26), which has an approximately 445-fold improved catalytic efficiency against (-)-cocaine.

In addition, the aforementioned mutant amino acid sequences can be truncated without substantially affecting the catalytic activity so that amino acid residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 30 and 28 are the amino acid sequences for residue 68-142 corresponding to mutants 1-5, respectively. In addition, with regard to mutants 1-4, it was found that amino acid residues before 117 and after 438 could be removed without substantially changing the activity of the mutant enzymes, resulting 35 in truncated amino acid sequences having SEQ ID NOS: 6, 12, 18 and 24, respectively. Finally with regard to mutant 5, amino acid residues before 117 and after 441 could be removed without substantially changing its activity resulting in SEQ ID NO: 30.

These aforementioned truncated sequences all of with similar catalytic activity is based on protein structures.

Further, the present invention is directed to a novel and unique pharmaceutical composition which comprises a butyrylcholinesterase variant, namely mutants 1-5, along 45 with a suitable pharmaceutical carrier. The pharmaceutical composition can be administered to an individual in an effective amount to lower the patient's cocaine blood concentration and in particular (-)-cocaine blood concentration.

In addition, the present invention is directed to a novel and 50 unique method for developing mutants which have enhanced catalytic efficiency. The generation method includes both a computational portion and an experimental portion. With regard to the computational portion, a variety of state of the art computational techniques including molecular modeling, 55 molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations, provide a virtual screening of possible BChE mutants. This virtual screening predicts which mutation will lead to a more stable transition state for a rate-determining step compared to 60 the corresponding separated reactants, i.e., free cocaine and free enzyme. The more stable the transition state, the lower the energy barrier, and the higher the catalytic efficiency. Following the computational portion, an experimental test is then conducted on the possible mutants of the computation 65 portion. The experimental test includes site-directed mutagenesis, protein expression, and enzyme activity assay.

The experimental tests are conducted on mutants which are predicted to have a high catalytic efficiency against (-)-cocaine than the wild-type BChE and/or other known BChE mutants against (-)-cocaine. Thus, the present method identifies or predicts mutants having high catalytic activity for cocaine hydrolysis by performing molecular modeling and MD simulations on the transition state structures of possible mutants of BChE. This method is an improvement over traditional random-search approaches, which, given the complex catalytic mechanism of cocaine hydrolysis, makes it difficult to improve the catalytic activity of BChE for cocaine hydrolysis.

The present invention in one form, concerns a butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

The present invention in another form thereof concerns a nucleic acid molecule comprising a nucleic acid sequence which encodes a butyrylcholinesterase variant peptide, the nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29.

The present invention in another form thereof concerns a pharmaceutical composition comprising a butyrylcholinesterase variant polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable pharmaceutical carrier.

The present invention in another form thereof concerns a method for treating a cocaine-induced condition comprising administering to an individual an effective amount of butyrylcholinesterase variant peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration.

The present invention is another form thereof concerns a method for treating a cocaine induced condition comprising administering to an individual an effective amount of a pharmaceutical composition comprising a butyrylcholinesterase variant having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier of claim 3 to an individual in an effective amount to lower blood cocaine concentration.

The present invention in yet another form thereof concerns a method for generating butyrylcholinesterase mutants. The method includes generating an initial structure of the transition state structure for the rate-determining step of the cocaine hydrolysis catalyzed by a possible butyrylcholinesterase mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen bonding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzyl ester and the oxyanion hole of the possible butyrylcholinesterase mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the wild-type butyrylcholinesterase, optionally, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. Finally, the butyrylcholinesterase mutant is generated.

In various alternative embodiments, the generating an initial structure of the transition state structure is based on reaction coordinate calculations for the wild-type butyrylcholinesterase. The generating butyrylcholinesterase mutant includes performing site-directed mutagenesis on a nucleic 5 acid sequence which includes wild-type butyrylcholinesterase to generate the mutant butyrylcholinesterase nucleic acid sequence. Using the mutant butyrylcholinesterase nucleic acid sequence, the protein encoded by the mutant nucleic acid sequences is expressed to produce mutant 10 butyrylcholinesterase and catalytic activity assay is performed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical geometry optimization may include calculating the hydrogen binding energies and evaluating the energy barriers only if the 15 overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than known butyrylcholinesterase mutants against (-)-cocaine.

In yet another alternative further embodiment, the method 20 for generating butyrylcholinesterase mutants further includes determining the rate-limiting step in the hydrolysis of (-)cocaine by the possible butyrylcholinesterase mutant by conducting molecular dynamics simulations and quantum mechanical/molecular mechanical calculations relating to the 25 the prior art. The first is the presently discovered BChE transition states for other reaction steps between (-)-cocaine by the possible butyrylcholinesterase mutant and calculating respective energy barriers, thereby establishing which of the reaction steps is the rate-determining one.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (-)cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) 35 in the enzyme-substrate complexes where FIG. 1A represents the non-prereactive enzyme-substrate complexes; and FIG. 1B represents the prereactive enzyme-substrate complexes in accordance with the present invention.

FIG. 2 shows the binding of structures of the simulated $_{40}$ non-prereactive and prereactive complexes of wild-type BChE binding with two entomers of cocaine in which FIG. 2A depicts BChE (-)-cocaine non-prereactive complex; FIG. 2B depicts BChE (-)-cocaine prereactive complex, FIG. 2C depicts BChE (+)-cocaine non-prereactive complex; and 45 FIG. 2D depicts BChE (+)-cocaine prereactive complex.

FIG. 3A shows the (-)-cocaine rotation in the BChE active site for the non-prereactive complex to the prereactive complex hindered by some residues at positions Y332, A328, and F329 residues in the non-prereactive complexes which are 50 significantly different from the corresponding positions in the prereactive complex; and FIG. 3B shows the (+)-cocaine

rotation in the BChE active site where none of the aforementioned residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex in accordance with the present invention.

FIG. 4A depicts the (-)-cocaine rotation in the active site of A328W/Y332A; FIG. 4B depicts the (-)-cocaine rotation in the active site of A328W/Y332G BChE from the non-preactive complex to the prereactive complex; and FIG. 4C depicts the (-)-cocaine rotation in the active site of wild-type BChE.

FIG. 5A is a plot of the key internuclear distances (in A) versus the time in the simulated TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A; and FIG. 5B for A199S/A328W/Y332G BChE.

FIG. 6 is a plot of key internuclear distances (in A) versus the time in the simulated TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE.

DETAILED DESCRIPTION OF THE PREFERRED **EMBODIMENTS**

The present invention has two major improvements over mutants, mutant 1, A199S/A328W/Y332G; mutant 2, A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/ A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/ Y332G; and mutant 5, A199S/F227A/S287G/A328W/ ³⁰ E441D each have a significantly higher catalytic efficiency. The second improvement is concerning the mutant designing or discovering process.

The BChE mutants 1-5 have full length amino acid sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, which are encoded by nucleic acid sequences having SEQ ID NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes the catalytic efficiency against (-)-cocaine for the five mutants.

In addition to the full length BChE mutants, the respective amino acid sequence can be truncated without substantially affecting the respective catalytic activity. With all mutants, residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the respective mutant BChE. Further, with regard to mutant 1-4, amino acids 1-116 and 439-574 can be omitted without substantially affecting its respective catalytic activity. With regard to mutant 5, amino acid residues 1-116 and 442-574 can be omitted without substantially affecting its catalytic activity. Table 1 also provides a summary of amino acid SEQ ID NOS and corresponding nucleic acid SEQ ID NOS for the aforementioned truncated mutant BChE sequences.

TABLE 1

Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.	Amino Acid SEQ ID NO.	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (-)-cocaine
1	A199S/ A328W/	1	2	3	4	5	6	65-fold
2	Y332G A199S/ F227A/	7	8	9	10	11	12	148-fold

10

				TABLE 1	-continued			
Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.	Amino Acid SEQ ID NO.	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (–)-cocaine
3	A328W/ Y332G A199S/ S287G/ A328W/	13	14	15	16	17	18	456-fold
4	Y332G A199S/ F227A/ S287G/ A328W/	19	20	21	22	22	24	1,003-fold
5	A199S/ F227A/ S287G/ A328W/ E441D	25	26	27	28	29	30	445-fold

(*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.)

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be formulated in a pharmaceutical composition along with a suitable pharmaceutical carrier known to one skilled in the art.

The present BChE variant polypeptides can be used in treating a cocaine-induced condition by administering to an individual, an effective amount of one of the BChE variant polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration. The BChE variant polypeptide may be administered in the form of a pharmaceutical composition in which the BChE variant is included with a suitable pharmaceutical carrier. Treatment of a cocaine induced condition using one of the aforementioned BChE variant polypeptides can be done in accordance with Zhan et al., page 2463.

The preferred dose for administration of a butyrylcholinesterase or peptide composition in accordance with the present invention is that amount which will be effective in lowering (-)-cocaine concentration in a patient's bloodstream, and one would readily recognize that this amount will 45 vary greatly depending on the nature of cocaine consumed, e.g., injected or inhaled, and the condition of a patient. An "effective amount" of butyrylcholinesterase mutant or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the 50 agent, such that the desired prophylactic or therapeutic effect is produced. Thus, the exact amount of the enzyme or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. Similarly, the dosing regimen should also be adjusted to suit the individual to whom the composition is administered and will once again vary with age, weight, metabolism, etc. of the individual. Accordingly, the "effective amount" of any particular butyrylcholinesterase composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation.

A unique method was used to determine potential BChE 65 mutants with projected increased catalytic activity for the hydrolysis of cocaine. The method provides a unique

approach which first models the potential BChE mutant interaction with cocaine followed by generating the BChE mutant if the predicted model indicates that the BChE variant should have enhanced catalytic activity. The method includes generating an initial structure of the transition state structure for the rate-determining step for the cocaine hydrolysis catalyzed by a possible BChE mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen binding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the oxyanion hole of the possible BChE mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)cocaine benzoyl ester and the possible BChE mutant, in the 4∩ transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the wild-type BChE, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. The QM/MM calculations make the computational predictions more reliable. Finally,

With regard to the molecular dynamics (MD) simulations and quantum mechanical/molecular mechanical (QM/MM) calculations, the first chemical reaction step of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants and, when needed, other reaction steps are modeled and calculated using molecular dynamics simulations and QM/MM calculations. Following this modeling, mutant BChE's are created using site-directed mutagenesis followed by protein expression. The aformentioned five mutants were identified by computational analysis and generated by sitedirected mutagenesis which have significantly enhanced (-)cocaine hydrolysis catalytic efficiency compared with wildtype BChE.

the BChE mutant is generated.

In the present method computational analysis in the form of molecular modeling of a potential BChE mutant and MD simulations and QM/MM calculations provide virtual screening of possible BChE mutants which have predicted enhanced catalytic activity for (-)-cocaine. For example, the MD simulations and QM/MM calculations predict which mutation will lead to a more stable transition state for the rate determining

55

step compared to the corresponding separated reagents, i.e., free cocaine and free possible mutant BChE, where the more stable transition state leads to a lower energy barrier and higher predicted catalytic efficiency. Only after the computational analysis predicts enhanced catalytic efficiency, is sitedirected mutagenesis conducted on wild-type BChE nucleic acid sequence to generate a mutant nucleic acid sequence which is then used to express a mutant BChE protein. The mutant BChE protein is then used in catalytic assays to determine the catalytic efficiency against (–)-cocaine.

The use of predictive, computational modeling of the present method for identifying mutant BChE candidates and the resulting mutant BChE are novel and unexpected over prior conventional methods which will now be readily apparent to one of ordinary skill in the art.

Using the present method, most discovered new mutants include a specific mutation (Y332G) on residue #332. No prior BChE mutant having the Y332G mutation had ever been reported previously; only mutations Y332A and Y332M on residue #332 had been tested previously by other researchers. Prior to the present invention, there was no reason to expect that a mutant including Y332G mutation should be better than the corresponding mutant including Y332A mutation or Y332M. Thus, the present mutants with a Y332G mutation which have enhanced catalytic activity represent a surprising and unexpected result over prior BChE mutants.

A Y332G mutant (single mutation) was first tested and found that the Y332G mutant had a slightly low (or approximately equal) catalytic efficiency than the wild-type. So, only an appropriate combination of different mutations on different residues could make the enzyme more active. As seen 30 below, the prior art did not reveal that any of the particular combinations tested was expected to have an improved catalytic efficiency. The present method is based on the present unique, extensive computational modeling and simulations of the detailed catalytic mechanism for both the wild-type BChE and the mutants.

The primary improvement of the present method over the prior art is that high-performance computational modeling and simulations of the detailed catalytic mechanism are performed, which includes modeling how cocaine binds with BChE and the subsequent structural transformation and chemical reaction process. The prior art only considered the cocaine binding with the enzyme (BChE) and was unable to examine the detailed catalytic reaction process after the BChE-cocaine binding. When molecular modeling was limited to studying the BChE-cocaine binding, one could only design a mutation to improve the BChE-cocaine binding without knowing whether the mutation will also speedup the subsequent chemical reaction process or not.

To overcome the obstacles of prior challenges to using computational techniques such as molecular docking and molecular dynamics simulation previously used by others which were based on an empirical force field which cannot be used to perform necessary reaction coordinate calculations for the catalytic reaction process, a variety of state-of-the-art computational techniques of homology modeling, molecular 55 docking, molecular dynamics, quantum mechanics (QM), and hybrid quantum mechanics/molecular mechanics (QM/ MM) were used for the rational design of the BChE mutants. The combined use of these computational techniques, including QM and QM/MM, led to the study of the detailed reaction coordinate of the BChE-catalyzed hydrolysis of cocaine which, for the first time, provided the detailed structures of all transition states and intermediates existing in the reaction process and the corresponding energetics. These extensive computational modeling and simulation studies provided for the rational design of possible BChE mutants that not only 65 can improve the BChE-cocaine binding, but also can speedup the subsequent chemical reaction process. As a result, one can

now quickly discover the BChE mutants with the significantly improved catalytic efficiency.

In addition, to the differences mentioned above, the present molecular modeling of the BChE-cocaine binding also differs from the prior modeling. The molecular modeling in the prior art considered only one binding mode for each BChE-cocaine system, without modeling the possible cocaine rotation in the BChE active site after the binding. The present method considers two different binding modes for each BChE-cocaine system and the structural transformation between them: nonprereactive and prereactive BChE-cocaine complexes. The present modeling provides more detailed information about the BChE-cocaine binding and the subsequent structural transformation.

The present method includes molecular dynamics simulations performed on the cocaine binding with both the wildtype BChE and the mutants whereas prior molecular dynamics simulations were only performed on the cocaine binding with the wild-type BChE. As is shown below in the following experiments, the computational prediction could be completely wrong without directly modeling and simulating cocaine binding with the proposed mutants.

The present invention will now be discussed with regard to the following non-limiting examples in the form of experiments which are provided to enhance understanding of the present invention but in no way limit its scope or applicability. EXPERIMENT 1: COMPUTATIONAL STUDY OF COCAINE BINDING WITH WILD-TYPE AND MUTANT

BCHE'S FOR A328W/Y332G, A328W/Y332A, AND A328W/Y332A/Y419S. A detailed computational study of cocaine binding with

wild-type and mutant BChE's starting from the available X-ray crystal structure of wild-type BChE was performed. The simulated mutants include A328W/Y332G, A328W/Y332A, and A328W/Y332A/Y419S, as simple geometric consideration of the binding site suggests that these mutations could be important for changing the (–)-cocaine rotation from the non-prereactive complex to the prereactive complex. Wet experimental tests were conducted on the catalytic activity of these mutants for (–)-cocaine in order to verify the computational predictions. All of the obtained results clearly demonstrate that molecular modeling and MD simulations of cocaine binding with BChE mutants provide a reliable computational approach to the rational design of high-activity mutants of BChE for the (–)-cocaine hydrolysis.

3D model of BChE. The initial coordinates of human BChE used in the computational studies came from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1P0P). The missing residues (D2, D3, E255, D378, D379, N455, L530, E531, and M532) in the X-ray crystal structure were built using the automated homology modeling tool Modeler disclosed by Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1990, 212 403, and Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1993, 234, 779, herein incorporated by reference, and InsightII software (Accelrys, Inc.) with the default parameters.

Molecular docking. Molecular docking was performed for each non-prereactive protein-ligand binding complex. The binding site was defined as a sphere with an approximately 15 Å radius around the active site residue S198. The amino acid residues included in the binding site model are not contiguous in the protein. Cocaine, considered as a ligand, was initially positioned at 17 Å in front of S198 of the binding site. Each BChE-cocaine binding complex was energy-minimized by using the steepest descent algorithm first until the maximum energy derivative is smaller than 4 kcal/mol/Å and then the conjugated gradient algorithm until the maximum energy derivative is smaller than 0.001 kcal/mol/Å. The energy minimization was followed by a 300 ps molecular dynamics (MD) simulation at T=298 K with a time step of 1 fs. During the energy minimization and MD simulation, only cocaine and

S

10

the residues of BChE included in the binding site were allowed to move, while the remaining part of the protein was fixed. The energy-minimization and MD simulation for these processes were performed by using the Amber force field implemented in the Discover_3/InsightII calculation engine, 5 disclosed by Cornell, W. D.; Cieplak, P.; Bayl), C. I.; Gould, I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. J. Am. Chem. Soc. 1995, 117, 5179. The non-bonded cut-off method and the dielectric constant were set up to group based (12 Å cut-off 10 distance) and distance dependent, respectively (ϵ =4r) in accordance with Harvey, S. C. Proteins 1989, 5, 78-92, herein incorporated by reference.

Molecular dynamic simulation in water. The initial coordinates used in the MD simulation of the non-prereactive 15 complexes were determined by using the molecular docking procedure described above, whereas the initial coordinates used in the MD simulation of the prereactive complexes were obtained from superimposing backbone of the X-ray crystal structure to that of the previously disclosed simulated prere- 20 active complex of Zhan et al between cocaine and a homology model of wild-type BChE. Each BChE-cocaine binding complex was neutralized by adding two chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å. The general procedure for carrying out the MD simulations in water is similar to that used in our previously reported other computational studies such as those in Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, R.L.J. Comput. Chem. 2003, 24, 368, herein all incorporated by reference. These simulations were performed by using the Sander module of Amber7 program as taught by Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang, 35 J.; Ross, W.S.; Simmerling, C.L.; Darden, T.A.; Merz, K.M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. (2002), AMBER 7, University of California, San Francisco, 40 herein incorporated by reference. The solvated system was optimized prior to the MD simulation. First, the proteinligand was frozen and the solvent molecules with counterions were allowed to move during a 5000-step minimization with the conjugate gradient algorithm and a 5 ps MD run at T=300 K. After full relaxation and the entire solvated system was energy-minimized, the system was slowly heated from T=10 K to T=300 K in 30 ps before the production MD simulation for 500 ps. The full minimization and equilibration procedure was repeated for each mutant. The MD simulations were performed with a periodic boundary condition in the NPT 50 ensemble at T=300 K with Berendsen temperature coupling and constant pressure (P=1 atm) with isotropic moleculebased scaling disclosed in Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. J. Comp. Phys. 1984, 81, 3684, herein incorporated by reference. The 55 SHAKE algorithm of Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. C. J. Comp. Phys. 1977, 23, 327 (herein incorporated by reference) was applied to fix all covalent bonds containing a hydrogen atom, a time step of 2 fs was used, and the non-bond pair list was updated every 10 steps. The pressure was adjusted by isotropic position scaling. The particle mesh Ewald (PME) method of Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. J. Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A residue-based cutoff of 10 Å was applied to the noncovalent interactions. 65 During the 500 ps production MD simulation, the coordinates of the simulated complex were saved every 1 ps.

Molecular docking and MD simulation procedures described above were performed to study cocaine binding with wild-type BChE and three mutants, i.e., A328W/ Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For each protein system (wild-type or mutant BChE), the protein binding with cocaine was considered in both the non-prereactive and prereactive enzyme-substrate complexes.

Most of the MD simulations in water were performed on a supercomputer, Superdome (shared-memory, with 4 nodes and 256 processors), at the Center for Computational Sciences, University of Kentucky. The other computations were carried out on SGI Fuel workstations and a 34-processors IBM x335 Linux cluster.

Experimental procedure. Site-directed mutagenesis of human BChE cDNA was performed by the QuikChange method of Braman, J.; Papworth, C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein incorporated by reference. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, all herein incorporated by reference, kindly provided by Dr. Lockridge at University of Nebraska Medical Center. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO2 incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure cocaine and benzoic acid, the product of cocaine hydrolysis by BChE, we used sensitive radiometric assays based on toluene extraction of [³H]cocaine labeled on its benzene ring were used in accordance with Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, herein incorporated by reference. In brief, to initiate reactions, 100 nCi of [³H]cocaine was mixed with 100 µl of culture medium. Reactions proceeded at 37° C. for varying times. Reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual cocaine. ³H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured timedependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{cat}/K_M) was determined.

Depicted in FIG. 1 are plots of some important distances in the MD-simulated (-)-cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-meansquare deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray crystal structure. MD trajectories for other complexes were similar to these two in FIG. 1, although the simulated average distances are different. Summarized in Table 2 are the average values of some important geometric parameters in the simulated complexes.

4∩

TABLE 2

BChE-cocaine	Av		$RMSD^d$					
binding"	<d1>_{non}</d1>	<d1></d1>	<d2></d2>	<d3></d3>	<d4></d4>	<t></t>	nonpre	re
wild-type	5.60	.27	.77	.71	.37	67	1.14	.27
wild-type with	7.64	.69	.88	.30	.83	61	1.15	.13
A328W/Y332A	7.11	.87	.30	.14	.01	51	1.58	1.65
A328W/Y332G	7.06	.96	.28	.52	.42	60	1.20	.35
A328W/Y332G/Y419S	5.18	.84	.64	.56	.97	64	2.66	.62

"Refers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a mutant BChE, unless indicated otherwise. ^bRefers to (+)-cocaine binding with wild-type human BChE.

^c<D1>_{non} and <D1> represent the average distances between the S198 O[?] atom and the carbonyl carbon of the cocaine benzoyl ester in the simulated non-prereactive and prereactive BChE-cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydrogen atoms of G116, G117, and A199 residues, respectively. <T> is the average value of the dihedral angle formed by the S198 O? atom and the plane of the carboxylate group of the cocaine benzoyl ester. See Scheme 2. ^dThe root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simu-

lated structure from those in the X-ray crystal structure of BChE. "nonpre" and "pre" refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively.

shows the binding structures of the simulated non-prereactive and prereactive complexes of wild-type BChE binding with the two enantiomers of cocaine. In the non-prereactive complexes with (-)- and (+)-cocaine, the methyl ester group of cocaine is positioned at the top of the H438 backbone, while the cocaine benzovl ester moiety is quasi-parallel to the C—O^{γ} side chain of S198 with a dihedral angle θ of -8° and 140°, respectively.



Scheme 2. Hydrolysis of (-)-cocaine and (+)-cocaine.

Here, θ refers to the dihedral angle formed by S198 O^{γ} and the plane of carboxylate group of the cocaine benzoyl ester as shown in the structure diagram below.

The simulated internuclear distances between the carbonyl 60 oxygen of cocaine benzoyl ester group and the NH hydrogen of G116, G117, and A199 are comparable for the two enantiomers. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O^{γ} are 5.60 Å and ₆₅ 5.18 Å for (-)- and (+)-cocaine, respectively. Comparing the simulated protein backbone structures to the X-ray crystal

(-)- and (+)-cocaine binding with wild-type BChE. FIG. 2 25 structure of Nicolet et al, one can see from FIG. 1 that the RMSD values are all smaller than 1.3 Å for the whole protein

> structures. The MD simulations of the prereactive complexes reveal that wild-type BChE binding with (-)-cocaine is essentially the same as the binding with (+)-cocaine in the binding site, except for the different positions of methyl ester group of the substrates. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O^{γ} are 3.27 and 3.69 Å for (-)-cocaine and (+)-cocaine, respectively. More-35 over, the (+)-cocaine is stabilized more effectively by the formation of strong hydrogen bonds with the backbone NH of residues G116, G117, and A199 as summarized above in Table 2. The cocaine benzoyl ester moiety is positioned quasiperpendicular to S198 C—O^{γ} with a dihedral angle θ of ~67° and $\sim 61^{\circ}$ for (-)- and (+)-cocaine, respectively.

> A comparison was made between the currently simulated structures of the BChE-cocaine binding with those simulated previously by using a homology model of BChE and it was noted that two major differences between the two sets of 45 structures. By using the X-ray crystal structure in accordance with Nicolet et al, the acyl loop is positioned on the top of the cocaine benzoyl ester moiety of the cocaine, whereas the acyl loop is far from the cocaine benzoyl ester moiety in the structure simulated starting from the homology model of 50 Zhan et al. The RMSD of the coordinates of backbone atoms in the previously simulated prereactive BChE-(-)-cocaine complex from those in the X-ray crystal structure of BChE is ~2.0 Å for the entire protein and ~3.0 Å for the acyl loop. The RMSD value became ~2.4 Å for the entire protein and ~3.3 Å 55 for the acyl loop, when the X-ray crystal structure was replaced by the MD-simulated prereactive BChE-(-)-cocaine complex starting from the X-ray crystal structure. Despite these structural differences, the benzovl ester group of the ligand is still close to the key residues (S197, G116, and G117) in the BChE binding site. Some significant differences are associated with the distances between the S198 O^{γ} atom and the carbonyl carbon of the cocaine benzoyl ester in nonprereactive complexes. The average values of this distance in the non-prereactive complexes were ~9.5 and ~8.5 Å for (-)and (+)-cocaine, respectively, when a homology model was used. Using the X-ray crystal structure to conduct the analysis, corresponding average values became ~5.6 and ~5.2 Å,

respectively. Therefore, both (-)- and (+)-cocaine became closer to the binding site when the homology model was replaced by the X-ray crystal structure. However, no significant changes of the binding in the prereactive complexes were observed when the used homology model was replaced by the 5 X-ray crystal structure. The average values of the simulated distance between the S198 O^{γ} atom and the carbonyl carbon of the cocaine benzoyl ester in the prereactive complexes are always close to ~3.5 Å for both (-)- and (+)-cocaine no matter whether the X-ray crystal structure or homology model of 10 BChE was used as the starting structure. The similar computational results obtained from the use of the X-ray crystal structure and homology model of BChE provides evidence that the fundamental structural and mechanistic insights obtained from the previous computational studies of Zhan et 15 al are reliable, despites the previous simulations were performed by using the homology model when the X-ray crystal structure was not available.

Further, the simulated structures of the non-prereactive BChE-cocaine complexes were superimposed with the cor-20 responding prereactive complexes. As shown in FIG. **3**, the (–)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex is hindered by some residues as the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly dif-25 ferent from the corresponding positions in the prereactive complex, whereas none of these residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex because these residues stay in nearly the same positions in the two BChE-(+)-30 cocaine complexes.

(-)-cocaine binding with BChE mutants. Now that the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex has been known to be the rate-determining step of the BChE-catalyzed hydrolysis of (-)-cocaine as 35 shown by Zhan et al, useful BChE mutants should be designed to specifically accelerate the change from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex. The question is whether MD simulation can be performed to help design BChE mutants that have higher 40 catalytic activity for (-)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O^Y is 7.6 Å for A328W/Y332A BChE and 7.1 Å for A328W/Y332G BChE, as seen in Table 2 above. In the simu- 45 lated prereactive complex, the average values of this important internuclear distance become 3.87 and 3.96 Å for A328W/Y332A and A328W/Y332G BChE's, respectively. Compared to the simulated wild-type BChE-(-)-cocaine prereactive complex, the average distances between the carbonyl 50 carbon of the cocaine benzovl ester and S198 O^{γ} in the prereactive complex of (-)-cocaine with A328W/Y332A and A328W/Y332G BChE's are all slightly longer, whereas the average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH of G116, G117, and A199 55 residues are all shorter. This provides evidence that (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/ Y332A and A328W/Y332G BChE's from the non- 60 prereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 (or G332), W328, and F329 residues as seen in FIG. 4, compared to the (-)-cocaine rotation in the active site of wild-type BChE. These results provide evidence that A328W/Y332A and 65 A328W/Y332G BChE's should be associated with lower energy barriers than the wild-type for the (-)-cocaine rotation

from the non-prereactive complex to the prereactive complex. Further, (–)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (–)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for the (–)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE.

Concerning (-)-cocaine binding with A328W/Y332A/ Y419S BChE, Y419 stays deep inside the protein and does not directly contact with the cocaine molecule. The Y419S mutation was tested because it was initially expected that this mutation would further increase the free space of the active site pocket so that the (-)-cocaine rotation could be easier. However, as seen in Table 2 above, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O^{γ} atom in the simulated prereactive complex was as long as 5.84 Å. The average distances between the carbonyl oxygen of the cocaine benzovl ester and the NH hydrolysis atoms of G116, G117, and A199 residues are between 4.56 and 6.97 Å; no any hydrogen bond between them. In addition to the internuclear distances, another interesting geometric parameter is the dihedral angle, $\theta,$ formed by S198 O^{γ} and the plane of the carboxylate group of the cocaine benzoyl ester. As seen in Table 2, the θ values in the prereactive complexes of cocaine with wild-type BChE and all of the BChE mutants other than A328W/Y332A/Y419S BChE all slightly deviate from the ideal value of 90° for the nucleophilic attack of S198 O^{γ} at the carbonyl carbon of cocaine. The θ value in the prereactive complex of (-)-cocaine with A328W/Y332A/ Y419S BChE is 164°, which is considerably different from the ideal value of 90°.

Catalytic activity. The aforementioned discussion provides evidence that the energy barriers for the (-)-cocaine rotation in A328W/Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex, the ratedetermining step for the BChE-catalyzed hydrolysis of (-)cocaine, should be lower than that in the wild-type BChE. Thus, the MD simulations predict that both A328W/Y332A and A328W/Y332G BChE's should have a higher catalytic activity than the wild-type BChE for (-)-cocaine hydrolysis. Further, the MD simulations also suggest that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE and, therefore, the catalytic activity of A328W/Y332G BChE for the (-)-cocaine hydrolysis should be slightly higher than the activity of A328W/Y332A BChE. In addition, the MD simulations predict that A328W/Y332A/Y419S BChE should have no catalytic activity, or have a considerably lower catalytic activity than the wild-type, for (-)-cocaine hydrolysis because (-)-cocaine binds with the mutant BChE in a way that is not suitable for the catalysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported to be 8.56× 10^6 M min⁻¹, which is 9.39 times of the k_{cat}/K_M value (9.11× 10^5 M min⁻¹) of the wild-type BChE. To examine these theoretical predictions of the relative activity for A328W/Y332G and A328W/Y332A/Y419S BChE's, a A328W/Y332A, A328W/Y332G, and A328W/Y332A/Y419S BChE was produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with all of three mutants under the same condition and compared the catalytic efficiency of the A328W/Y332A for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data, the ratio of the $k_{cat}/$ K_M value of A328W/Y332G BChE to the k_{cal}/K_M value of A328W/Y332A BChE for the (–)-cocaine hydrolysis was determined to be ~2.08, or A328W/Y332G BChE has a k_{cal}/K_M value of ~1.78×10⁷M min⁻¹ for the (–)-cocaine hydrolysis. The radiometric data show no significant catalytic activity 5 for A328W/Y332A/Y419S BChE. These experimental data are consistent with the theoretical predictions based on the MD simulations.

Conclusion. Molecular modeling, molecular docking, and molecular dynamics (MD) simulations were performed to 10 study cocaine binding with human butyrylcholinesterase (BChE) and its mutants, based on a recently reported X-ray crystal structure of human BChE. The MD simulations of cocaine binding with wild-type BChE led to average BChEcocaine binding structures similar to those obtained recently from the MD simulations based on a homology model of BChE, despite the significant difference found at the acyl binding pocket. This confirms the fundamental structural and mechanistic insights obtained from the prior computational studies of Zhan et al based on a homology model of BChE, 20 e.g., the rate-determining step for BChE-catalyzed hydrolysis of biologically active (-)-cocaine is the (-)-cocaine rotation in the BChE active site from the non-prereactive BChE-(-)cocaine complex to the prereactive complex.

The MD simulations further reveal that the (-)-cocaine 25 rotation in the active site of wild-type BChE from the nonprereactive complex to the prereactive complex is hindered by some residues such that the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from those in the prereactive complex. Com- 30 pared to (-)-cocaine binding with wild-type BChE, (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/Y332A and A328W/Y332G BChE's from the non- 35 prereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 or G332, W328, and F329 residues. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's are associated with lower energy barriers than wild-type BChE for the (-)- 40 cocaine rotation from the non-prereactive complex to the

prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for (-)-cocaine rotation in A328W/Y332A BChE should be slightly lower than that in A328W/Y332A BChE. It has also been demonstrated that (-)-cocaine binds with A328W/Y332A/Y419S BChE in a way that is not suitable for the catalysis.

Based on the computational results, both A328W/Y332A and A328W/Y332G BChE's have catalytic activity for (–)-cocaine hydrolysis higher than that of wild-type BChE and the activity of A328W/Y332G BChE should be slightly higher than that of A328W/Y332A BChE, whereas A328W/Y332A/Y419S BChE is expected to lose the catalytic activity. The computational predictions are completely consistent with the experimental kinetic data, providing evidence that the used computational protocol, including molecular modeling, molecular docking, and MD simulations, is reliable in prediction of the catalytic activity of BChE mutants for (–)-cocaine hydrolysis.

EXPERIMENT 2: MD SIMULATIONS AND QUAN-TUM MECHANICAL/MOLECULAR MECHANICAL (QM/MM) CALCULATIONS RELATING TO A 199S/ A328W/Y332G MUTANT (MUTANT 1) (SEQ ID NO: 1).

Generally speaking, for rational design of a mutant enzyme with a higher catalytic activity for a given substrate, one needs to design a mutation that can accelerate the rate-determining step of the entire catalytic reaction process while the other steps are not slowed down by the mutation. Reported computational modeling and experimental data indicated that the formation of the prereactive BChE-(–)-cocaine complex (ES) is the rate-determining step of (–)-cocaine hydrolysis catalyzed by wild-type BChE as disclosed by Sun et al, Zhan et al and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys. Chem. B 2005, 109, 4776, herein incorporated by reference, whereas the rate-determining step of the corresponding (+)cocaine hydrolysis is the chemical reaction process consisting of four individual reaction steps disclosed by Zhan et al and shown in Scheme 3 and Scheme 4 below.



Ξ

Η

È





ć

È

Ë,

S198

A199

Ξ

È

Scheme 3. Schematic representation of BChE-catalyzed hydrolysis of (-)-cocaine. Only QM-treated high-layer part of the reaction system in the QM/MM calculations are drawn. Notation [H] refers to a non-hydrogen atom in the MM-treated low-layer part of the protein and the cut covalent bond 5 with this atom is saturated by a hydrogen atom. The dash lines in the transition state structures represent the transition bonds.

This mechanistic understanding is consistent with the experimental observation of Sun et al, that the catalytic rate constant of wild-type BChE against (+)-cocaine is pH-depen- 10 dent, whereas that of the same enzyme against (-)-cocaine is independent of the pH. The pH-dependence of the rate constant for (+)-cocaine hydrolysis is clearly associated with the protonation of H438 residue in the catalytic triad (S198, H438, and E325). For the first and third steps of the reaction 15 process, when H438 is protonated, the catalytic triad cannot function and, therefore, the enzyme becomes inactive. The lower the pH of the reaction solution is, the higher the concentration of the active enzyme is. Hence, the rate constant 20 was found to decrease with decreasing the pH of the reaction solution for the enzymatic hydrolysis of (+)-cocaine.

Based on the above mechanistic understanding, the efforts for rational design of the BChE mutants reported in literature have been focused on how to improve the ES formation 25 process. Indeed, several BChE mutants, including A328W, A328W/Y332A, A328W/Y332G, and F227A/S287G/ A328W/Y332M, have been found to have a significantly higher catalytic efficiency (k_{cat}/K_M) against (-)-cocaine; these mutants of BChE have an approximate 9 to 34-fold 30 improved catalytic efficiency against (-)-cocaine. Experimental observation also indicated that the catalytic rate constant of A328W/Y332A BChE is pH-dependent for both (-)and (+)-cocaine. The pH-dependence reveals that for both (-)- and (+)-cocaine, the rate-determining step of the 35 hydrolysis catalyzed by A328W/Y332A BChE should be either the first or the third step of the reaction process. Further, if the third step were rate determining, then the catalytic efficiency of the A328W/Y332A mutant against (-)-cocaine should be as high as that of the same mutant against (+)- 40 cocaine because the (-)- and (+)-cocaine hydrolyses share the same third and fourth steps (see Scheme 3). However, it has also been observed that the A328W/Y332A mutant only has a ~9-fold improved catalytic efficiency against (-)-cocaine, whereas the A328W/Y332A mutation does not change the 45 high catalytic activity against (+)-cocaine. This analysis of the experimental and computational data available in literature clearly shows that the rate-determining step of (-)-cocaine hydrolysis catalyzed by the A328W/Y332A mutant should be the first step of the chemical reaction process. 50 Further, recently reported computational modeling also suggests that the formation of the prereactive BChE-(-)-cocaine complex (ES) is hindered mainly by the bulky side chain of Y332 residue in wild-type BChE, but the hindering can be removed by the Y332A or Y332G mutation. Therefore, start- 55 ing from the A328W/Y332A or A328W/Y332G mutant, the truly rational design of further mutation(s) to improve the catalytic efficiency of BChE against (-)-cocaine should aim to decrease the energy barrier for the first reaction step without significantly affecting the ES formation and other chemi- 60 cal reaction steps.

The following rational design of a high-activity mutant of BChE against (–)-cocaine is based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecu- 65 lar dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations

were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChEcatalyzed hydrolysis of (-)-cocaine. The simulated and calculated results indicate that the transition-state structure can be stabilized better by the protein environment in A199S/ A328W/Y332G mutant of BChE than that in the wild-type. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/A328W/Y332G mutant against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/A328W/ Y332G mutant has a significantly improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)cocaine.

MD simulations. It should be stressed that a critical issue exists with regard to any MD simulation on a transition state. In principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface. Hence, MD simulation using a classical force field cannot directly simulate a transition state without any restraint on the geometry of the transition state. Nevertheless, if one can technically remove the freedom of imaginary vibration in the transition state structure, then the number of vibrational freedoms (normal vibration modes) for a nonlinear molecule will decrease from 3N-6. The transition state structure is associated with a local minimum on the potential energy surface within a subspace of the reduced vibrational freedoms, although it is associated with a firstorder saddle point on the potential energy surface with all of the 3N-6 vibrational freedoms. Theoretically, the vibrational freedom associated with the imaginary vibrational frequency in the transition state structure can be removed by appropriately freezing the reaction coordinate. The reaction coordinate corresponding to the imaginary vibration of the transition state is generally characterized by a combination of some key geometric parameters. These key geometric parameters are bond lengths of the forming and breaking covalent bonds for BChE-catalyzed hydrolysis of cocaine, as seen in Scheme 3. Thus, one just needs to maintain the bond lengths of the forming and breaking covalent bonds during the MD simulation on a transition state. Technically, one can maintain the bond lengths of the forming and breaking covalent bonds by simply fixing all atoms within the reaction center, by using some constraints on the forming and breaking covalent bonds, or by redefining the forming and breaking covalent bonds. It should be pointed out that the only purpose of performing such type of MD simulation on a transition state is to examine the dynamic change of the protein environment surrounding the reaction center and the interaction between the reaction center and the protein environment. For this study, of interest is the simulated structures, as the total energies calculated in this way are meaningless.

The initial BChE structures used in the MD simulations were prepared based on the previous MD simulation in accordance with Hamza et al on the prereactive ES complex for wild-type BChE with (–)-cocaine in water by using Amber7 program package. The previous MD simulations on the prereactive BChE-(–)-cocaine complex (ES) started from the X-ray crystal structure of Nicolet et al deposited in the Protein Data Bank (pdb code: 1P0P). The present MD simulation on the transition state for the first step (TS1) was performed in such a way that bond lengths of the partially formed and

partially broken covalent bonds in the transition state were all constrained to be the same as those obtained from our previous ab initio reaction coordinate calculations on the model reaction system of wild-type BChE in accordance with Zhan et al. The partially formed and partially broken covalent bonds in the transition state will be called "transition" bonds below, for convenience. A sufficiently long MD simulation with the transition bonds constrained should lead to a reasonable protein environment stabilizing the reaction center in the transition-state structure simulated. Further, the simulated TS1 structure for wild-type BChE with (–)-cocaine was used to build the initial structures of TS1 for the examined BChE mutants with (–)-cocaine; only the side chains of mutated residues needed to be changed.

The partial atomic charges for the non-standard residue atoms, including cocaine atoms, in the TS1 structures were calculated by using the RESP protocol implemented in the Antechamber module of the Amber7 package following electrostatic potential (ESP) calculations at ab initio HF/6-31G* level using Gaussian03 program known in the art. The geometries used in the ESP calculations came from those obtained from the previous ab initio reaction coordinate calculations of Zhan et al, but the functional groups representing the oxyanion hole were removed. Thus, residues G116, G117, and ²⁵ A199 were the standard residues as supplied by Amber7 in the MD simulations. The general procedure for carrying out the MD simulations in water is essentially the same as that used in our previously reported other computational studies including Zhan et al, Hamza et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, 35 R. L. J. Comput. Chem. 2003, 24, 368, (d) Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. Bioorg. Med. Chem. 2005, 13, 4544, herein all incorporated by reference. Each aforementioned starting TS1 structure was neutralized by adding chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å as described by Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Klein, M. L. J. Chem. Phys. 1983, 79, 926, herein incorporated by reference. The total numbers of atoms in the 45 solvated protein structures for the MD simulations are nearly 70,000, although the total number of atoms of BChE and (-)-cocaine is only 8417 (for the wild-type BChE). All of the MD simulations were performed by using the Sander module of Amber7 package. The solvated systems were carefully equilibrated and fully energy minimized. These systems were gradually heated from T=10 K to T=298.15 K in 30 ps before running the MD simulation at T=298.15 K for 1 ns or longer, making sure that a stable MD trajectory was obtained for each 55 of the simulated TS1 structures. The time step used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble at T=298.15 K with Berendsen temperature coupling and P=1 atm with isotropic molecule-based scaling 60 were applied. The SHAKE algorithm was used to fix all covalent bonds containing hydrogen atoms. The non-bonded pair list was updated every 10 steps. The particle mesh Ewald (PME) method in accordance with Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen, L. G. J. 65 Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A

28

residue-based cutoff of 10 Å was utilized to the non-covalent interactions. The coordinates of the simulated systems were collected every 1 ps during the production MD stages.

QM/MM calculations. For each TS1 structure examined, after the MD simulation was completed and a stable MD trajectory was obtained, all of the collected snapshots of the simulated structure, excluding those before the trajectory was stabilized, were averaged and further energy-minimized. The energy-minimized average structure (with the transition bonds constrained) was used as an initial geometry to carry out a further geometry optimization by using the ONIOM approach of Dapprich, S.; Komaromi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. J. Mol. Struct. (Theochem) 1999, 461, 1-21, herein incorporated by reference, implemented in the Gaussian03 program of Frisch, M. J. et al Gaussian 03, Revision A.1, Gaussian, Inc., Pittsburgh, Pa., 2003, herein incorporated by reference. Two layers were defined in the present ONIOM calculation: the high layer, as depicted in Scheme 3 above, was calculated quantum mechanically at the ab initio HF/3-21G level, whereas the low layer was calculated molecular mechanically by using the Amber force field as used in our MD simulation and energy minimization with the Amber7 program. The ONIOM calculations at the HF/3-21G: Amber level in this study are a type of QM/MM calculations of Vreven, T.; Morokuma, K. J. Chem. Phys. 2000, 113, 2969-2975 and Frisch, M.; Vreven, T.; Schlegel, H. B.; Morokuma, K. J. Comput. Chem. 2003, 24, 760-769, herein both incorporated by reference. Previous reaction coordinate calculations with an active site model of wild-type BChE demonstrate that the HF/3-21G level is adequate for the geometry optimization of this enzymatic reaction system shown by Zhan et al, although the final energy calculations for calculating the energy barriers must be carried out at a higher level. As depicted in Scheme 3, for all of these QM/MM calculations, the same part of the enzyme was included in the QMtreated high layer. So, the QM-treated high layer included (-)-cocaine, key functional groups from the catalytic triad (S198, H438, and E325), and the three residues, i.e., G116, G117, and A199 (or S199 for a particular mutant, see Scheme 4), of the possible oxyanion hole, whereas the entire enzyme structure of BChE was included in the MM-treated low layer. A language computer program was developed to automatically generate the input files for the ONIOM calculations following the MD simulations and subsequent energy minimizations in order to make sure that the atom types used for all low-layer atoms are the same as what were used in the Amber7. During the TS1 geometry optimization using the two-layer ONIOM, the length of a key transition C-O bond was fixed which dominates the reaction coordinate; all of the other transition bond lengths were relaxed. The C and O atoms in the key transition C-O bond are the carbonyl carbon of (–)-cocaine benzoyl ester and the O^{γ} atom of S198, respectively, according to the previous reaction coordinate calculations with an active site model of wild-type BChE of Zhan et al.

Most of the MD simulations and QM/MM calculations were performed in parallel on an HP supercomputer (Superdome, with 256 shared-memory processors) at the Center for Computational Sciences, University of Kentucky. Some of the computations were carried out on a 34-processors IBM x335 Linux cluster and SGI Fuel workstations.







US 7,731,957 B1

Scheme 4. Schematic representation of the first reaction step for (–)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

Experimental materials. Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from Stratagene (La Jolla, Calif.). ³H-(-)-cocaine (50 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, Mass.). The expression plasmid pRc/CMV was a gift from Dr. O. Lockridge, University of Nebraska Medical Center (Omaha, Nebr.). All oligonucleotides were synthesized by the Integrated DNA Technologies, Inc. The QIAprep Spin Plasmid Miniprep Kit and Qiagen plasmid purification kit and QIAquick PCR purification kit were obtained from Qiagen (Santa Clarita, Calif.). Human embryonic kidney 293T/17 cells were from ATCC (Manassas, Va.). Dulbecco's modified Eagle's medium 15 (DMEM) was purchased from Fisher Scientific (Fairlawn, N.J.). Oligonucleotide primers were synthesized by the Integrated DNA Technologies and Analysis Facility of the University of Kentucky. 3,3',5,5'-Tetramethylbenzidine (TMB) was obtained from Sigma (Saint Louis, Mo.). Anti-butyryl- 20 cholinesterase (mouse monoclonal antibody, Product # HAH002-01) was purchased from AntibodyShop (Gentofte, Denmark) and Goat anti-mouse IgG HRP conjugate from Zymed (San Francisco, Calif.).

Site-directed mutagenesis, protein expression, and BChE 25 activity assay. Site-directed mutagenesis of human BChE cDNA was performed by using the QuikChange method of Braman et al. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with (a) Masson, P.; Legrand, P.; Bartels, C. F.; Fro- 30 ment, M.-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, 35 O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Using plasmid DNA as 40 template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into 45 Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 50 2000 complexes of 4 μg plasmid DNA per each well. Cells were incubated at 37° C. in a CO2 incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was har- 55 vested for a BChE activity assay. To measure (-)-cocaine and benzoic acid, the product of (-)-cocaine hydrolysis catalyzed by BChE, sensitive radiometric assays were used based on toluene extraction of $[^{3}H]$ -(–)-cocaine labeled on its benzene ring in accordance with Sun et al. In brief, to initiate the 60 enzymatic reaction, 100 nCi of [³H]-(-)-cocaine was mixed with 100 µl of culture medium. The enzymatic reactions proceeded at room temperature (25° C.) for varying time. The reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a 65 positive charge on the residual (-)-cocaine. [3H]benzoic acid was extracted by 1 ml of toluene and measured by scintilla-

tion counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{car}/K_M) was determined along with the use of an enzyme-linked immunosorbent assay (ELISA) described below.

Enzyme-linked immunosorbent assay (ELISA). The ELISA buffers used in the present study are the same as those described in the literature such as (a) Brock, A.; Mortensen, V.; Loft, A. G. R.; Nergaard-Pedersen, B. J. Clin. Chem. Clin. Biochem. 1990, 28, 221-224, (b) Khattab, A. D.; Walker, C. H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. Environmental Toxicology and Chemistry 1994, 13, 1661-1667, herein both incorporated by reference. The coating buffer was 0.1 M sodium carbonate/bicarbonate buffer, pH 9.5. The diluent buffer (EIA buffer) was potassium phosphate monobasic/ potassium phosphate monohydrate buffer, pH 7.5, containing 0.9% sodium chloride and 0.1% bovine serum albumin. The washing buffer (PBS-T) was 0.01 M potassium phosphate monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the assays were performed in triplicate. Each well of an ELISA microtiter plate was filled with 100 µl of the mixture buffer consisting of 20 µl culture medium and 80 µl coating buffer. The plate was covered and incubated overnight at 4° C. to allow the antigen to bind to the plate. The solutions were then removed and the wells were washed four times with PBS-T. The washed wells were filled with 200 µl diluent buffer and kept shaking for 1.5 h at room temperature (25° C.). After washing with PBS-T for four times, the wells were filled with 100 µl antibody (1:8000) and were incubated for 1.5 h, followed by washing for four times. Then, the wells were filled with 100 µl goat anti-mouse IgG HRP conjugate complex diluted to a final 1:3000 dilution, and were incubated at room temperature for 1.5 h, followed by washing for four times. The enzyme reactions were started by addition of 100 µl substrate (TMB) solution. The reactions were stopped after 15 min by the addition of 100 µl of 2 M sulfuric acid, and the absorbance was read at 460 nm using a Bio-Rad ELISA plate reader.

Hydrogen bonding revealed by the MD simulations. In accordance with one aspect of the present invention, namely the generation of high-activity mutants of BChE against (-)cocaine, the present invention includes predicting some possible mutations that can lower the energy of the transition state for the first chemical reaction step (TS1) and, therefore, lower the energy barrier for this critical reaction step. Apparently, a mutant associated with the stronger hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of the BChE mutant in the TS1 structure may potentially have a more stable TS1 structure and, therefore, a higher catalytic activity for (-)-cocaine hydrolysis. Hence, the hydrogen bonding with the oxyanion hole in the TS1 structure is a crucial factor affecting the transition state stabilization and the catalytic activity. The possible effects of some mutations on the hydrogen bonding were examined by performing MD simulations and QM/MM calculations on the TS1 structures for (-)-cocaine hydrolysis catalyzed by the wild-type and various mutants BChE's.

The MD simulation in water was performed for 1 ns or longer to make sure a stable MD trajectory was obtained for each simulated TS1 structure with the wild-type or mutant BChE. The MD trajectories actually became stable quickly, so were the H \ldots O distances involved in the potential hydrogen bonds between the carbonyl oxygen of (–)-cocaine and the oxyanion hole of BChE.

Depicted in FIG. **5** are plots of four important $H \dots O$ distances in the MD-simulated TS1 structure versus the simulation time for (–)-cocaine hydrolysis catalyzed by A328W/

Y332A or A199S/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain which exists only in A199S/A328W/Y332G BChE. RMSD represents the root-mean-square deviation (in A) of the simulated positions of the protein backbone atoms from those in the initial structure. The H . . . O distances in the simulated TS1 structures corresponding to the wild-type BChE and the two mutants are summarized in Table 3. The H... O distances between the carbonyl oxygen of (-)-cocaine and the peptidic 15 NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 2 and FIG. 1. D4 in Table 3 and FIG. 5 refers to the H . . . O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 20 structure corresponding to the A199S/A328W/Y332G mutant, mutant (1) (SEQ ID NO: 2).

TABLE 3

Summary of the MD-simulated and QM/MM-optimized key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).

				Dista			
Transition State		Method	D1	D2	D3	D4	Total HBE ^{b}
TS1 for (-)-cocaine	MD	Average	4.59	2.91	1.92		-5.5 (-4.6)
hydrolysis catalyzed		Maximum	5.73	4.14	2.35		
by wild-type BChE		Minimum	3.35	1.97	1.61		
		Fluctuation	0.35	0.35	0.12		
		QM/MM	4.10	2.21	2.05		-4.2
TS1 for (-)-cocaine	MD	Average	3.62	2.35	1.95		-6.2 (-4.9)
hydrolysis catalyzed		Maximum	4.35	3.37	3.02		
by A328W/Y332A		Minimum	2.92	1.78	1.61		
mutant of BChE		Fluctuation	0.23	0.27	0.17		
		QM/MM	3.39	2.05	2.47		-3.3
TS1 for (-)-cocaine	MD	Average	5.30	2.21	1.94	2.15	-9.7 (-7.4)
hydrolysis catalyzed		Maximum	6.08	3.06	2.47	3.27	
by A199S/A328W/		Minimum	4.57	1.71	1.66	1.56	
Y332G mutant of		Fluctuation	0.22	0.20	0.13	0.29	
BChE		QM/MM	4.83	2.09	1.91	2.59	-7.46

^aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/A328W/Y332G mutant.

side chain in the A199S/A328W/Y332G mutant. The total HBE value under MD is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances. The total HBE value under QM/MM was evaluated by using the QM/MM-optimized distances.

As seen in Table 3, the simulated H . . . O distance D1 is $_{55}$ always too long for the peptidic NH of G116 to form a N—H . . . O hydrogen bond with the carbonyl oxygen of (–)-cocaine. In the simulated TS1 structure corresponding to wild-type BChE, the carbonyl oxygen of (–)-cocaine formed a firm N—H . . . O hydrogen bond with the peptidic NH 60 hydrogen atom of A199 residue; the simulated H . . . O distance was 1.61 to 2.35 Å, with an average value of 1.92 Å. Meanwhile, the carbonyl oxygen of (–)-cocaine also had a partial N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated H . . . O 65 distance was 1.97 to 4.14 Å (the average value: 2.91 Å). In the simulated TS1 structure corresponding to the A328W/Y332A

mutant, the simulated average H . . . O distances with the peptidic NH hydrogen of G117 and A199 are 2.35 and 1.95 Å, respectively. These distances suggest a slightly weaker N—H . . . O hydrogen bond with A199, but a stronger N—H . . . O hydrogen bond with G117, in the simulated TS1 structure corresponding to the A328W/Y332A mutant. The overall strength of the hydrogen bonding between the carbonyl oxygen of (–)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A mutant.

However, the story for the simulated TS1 structure associated with the A199S/A328W/Y332G mutant was remarkably different. As one can see from Scheme 4, FIG. 5, and Table 3, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an O—H ... O hydrogen bond, in addition to the two N—H ... O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H ... O distances with the peptidic NH hydroxyl hydrogen of S199 are 2.21, 1.94, and 2.15 Å, respectively. Due to the additional O—H ... O hydrogen

As seen in Table 3, the simulated H . . . O distance D1 is solution ways too long for the peptidic NH of G116 to form a —H . . . O hydrogen bond with the carbonyl oxygen of)-cocaine. In the simulated TS1 structure corresponding to

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (–)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H . . . O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite in accordance with (a) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew. R. K.; Olson, A. J. *J. Comput. Chem.* 1998, 19, 1639-1662, and based on the general HBE equation, HBE(r)~5 $\epsilon r_0^{12}/r^{12}$ -6 $\epsilon r_0^{10}/r^{10}$, in which r is the H... O distance in the considered hydrogen bond and r_0 is the minimum value of the H . . . O distance for which the HBE equation can be used. For the calculation, $r_0=1.52$ Å, because it is the shortest H . . . O distance found in all of our MD 5 simulations. The ϵ value was determined by using the condition that HBE(r)=-5.0 kcal/mol when r=1.90 Å, herein incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated structure. 10 The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)cocaine and the oxyanion hole in each simulated TS1 struc- 15 ture is given in Table 3.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H ... O distance. As seen in Table 3, the total hydrogen-bonding energies (i.e., -4.6, -4.9, and -7.4 kcal/mol for the wild-type, A328W/Y332A, and A1998/ 20 A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, and -9.7 kcal/mol) estimated in the aforementioned way. However, the two sets of total HBE values are qualitatively 25 consistent in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the simu- 30 lated TS1 structure for A199S/A328W/Y332G BChE is significantly higher than that for the wild-type and A328W/ Y332A BChE's.

Hydrogen bonding based on the QM/MM calculations. The above conclusion obtained from the MD simulations was 35 further examined by carrying out QM/MM calculations. Although this enzymatic reaction system is too large to calculate the QM/MM force constant matrix required in the automated search for a first-order saddle point corresponding to TS1, a partial geometry optimization was performed by 40 fixing the length of the transition C—O bond between the carbonyl carbon of (-)-cocaine and the O^{γ} atom of S198 in the QM/MM calculation. This transition C-O bond length dominates the reaction coordinate, according to the previous first-principle reaction coordinate calculations, in accordance 45 with Zhan et al, with an active model of wild-type BChE. In the partial geometry optimization, the transition C-O bond length was fixed at that in the TS1 geometry optimized previously by performing the first-principle reaction coordinate calculation with an active site model of wild-type BChE. This 50 partially optimized geometry should be close to the precisely defined TS1 geometry associated with a first-order saddle point on the potential energy surface, particularly for the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of BChE.

The QM/MM results summarized in Table 3 demonstrate two hydrogen bonds in each of the QM/MM-optimized TS1 structures. Specifically, D2=2.21 Å and D3=2.05 Å in the optimized TS1 structure for wild-type BChE; D2=2.05 Å and D3=2.47 Å in the optimized TS1 structure for the A328W/ 60 Y332A mutant; D2=2.09 Å, D3=1.91 Å, and D4=2.59 Å in the optimized TS1 structure for the A199S/A328W/Y332G mutant. Although the QM/MM-optimized individual H . . . O distances and the estimated HBE values are different from the corresponding values for individual hydrogen bonds, the relative total HBE values (i.e., -4.2, -3.3, and -7.46 kcal/mol for the wild-type, A328W/Y332A, and A199S/A328W/Y332G

BChE's, respectively) estimated from these optimized distances are qualitatively consistent with the corresponding total HBE values (i.e., -4.6, -4.9, and -7.4 kcal/mol) estimated from the MD-simulated average H . . . O distances.

It should be pointed out that the absolute HBE values estimated in this study are not expected to be accurate, as different computational approaches led different HBE values. Nevertheless, for the purpose of our computational design of a high-activity mutant of BChE, one only needs to know the relative strength of the hydrogen bonding based on the estimated relative total HBE values of different mutants. The three sets of total HBE values (Table 3) estimated from the MD-simulated and QM/MM-optimized H . . . O distances all consistently demonstrate: (1) the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE should be close to that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by wild-type BChE; (2) the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE.

Catalytic activity. The computational results discussed above suggest that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature, namely Sun et al and Hamza et al, also indicate that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This provides evidence of a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A and A199S/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, both the MD simulations and QM/MM calculations predict that A199S/ A328W/Y332G BChE should have a higher catalytic activity than A328W/Y332A BChE for (-)-cocaine hydrolysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported by Sun et al to be ~8.6×10⁶ M min⁻, which is ~9.4 times of the k_{cat}/K_M value $(-9.1 \times 10^5 \text{ M min}^-)$ of wild-type BChE. To examine the theoretical prediction of the higher catalytic activity for A1998/ A328W/Y332G BChE, A328W/Y332A and A1998/A328W/ Y332G mutants of BChE were produced through site-55 directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/A328W/Y332G BChE's to that of the wild-type for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured timedependent radiometric data and the ELISA data, the ratio of the k_{cat}/K_M value of A328W/Y332A BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the k_{cat}/K_M value of A199S/ A328W/Y332G BChE to the k_{cat}/K_M value of A328W/ Y332A BChE for (-)-cocaine hydrolysis was determined to be ~7.2. These data indicate that the ratio of the k_{cat}/K_M value of A199S/A328W/Y332G BChE to the k_{cat}/K_M value of 5 wild-type BChE for (-)-cocaine hydrolysis should be ~7.2× 8.6=~62 or ~7.2×9.4=~68. Thus, A199S/A328W/Y332G BChE has a ~(65±6)-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/ A328W/Y332G BChE has a k_{cat}/K_M value of ~(5.9±0.5)×10⁷ 10 M min⁻¹ for (-)-cocaine hydrolysis.

Very recently reported F227A/S287G/A328W/Y332M BChE (i.e., AME-359, k_{car}/K_M =3.1×10⁷ M min⁻) has a ~34fold improved catalytic efficiency for (–)-cocaine hydrolysis. AME-359 has the highest catalytic efficiency against (–)cocaine within all of the BChE mutants reported in literature prior to the present study. The catalytic efficiency for our A199S/A328W/Y332G BChE is about two times of that for AME-359 against (–)-cocaine.

Conclusion. Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/ MM) calculations on the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by 25 butyrylcholinesterase (BChE) mutants lead to a better understanding of the effects of protein environment on the transition state stabilization. All of the computational results consistently demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester 30 and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by the wildtype and A328W/Y332A BChE's. Thus, both the MD simulations and QM/MM calculations predict that A1998/ A328W/Y332G BChE should have a lower energy barrier for the chemical reaction process and, therefore, a higher catalytic efficiency (k_{cat}/K_M) for (-)-cocaine hydrolysis; A328W/ 40 Y332A BChE has been known to have a ~9-fold improved catalytic efficiency for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a ~(65±6)-fold improved catalytic efficiency for 45 A199S/A328W/Y332G BChE against (-)-cocaine compared to the wild-type BChE. The k_{cat}/K_M value determined for A199S/A328W/Y332G BChE is about two times of the k_{ca}/ K_M value for F227A/S287G/A328W/Y332M BChE (i.e., AME-359, which has the highest catalytic efficiency within $_{50}$ all BChE mutants reported prior to the present study) against (-)-cocaine. The encouraging outcome of this study suggests that the transition-state modeling is a promising approach for rational design of high-activity mutants of BChE as a thera-55 peutic treatment of cocaine abuse.

EXPERIMENT 3: MD SIMULATION AND GENERA-TION OF MUTANT A199S/S287G/A328W/Y332G BCHE (MUTANT 3) (SEQ ID NO: 14).

The following simulation and mutant generation relate to 60 A199S/S287G/A328W/Y332G (mutant 3) as a rational design of a high-activity mutant of BChE against (–)-cocaine based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simu- 65 lations were performed to model the protein environmental effects on the stabilization of the transition-state structure for

38

BChE-catalyzed hydrolysis of (-)-cocaine as described above for mutant A199S/A328W/Y332G (mutant 1). The simulated results indicate that the transition-state structure can be stabilized much better by the protein environment in A199S/S287G/A328W/Y332G BChE than that in wild-type BChE and in other BChE mutants examined. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/S287G/A328W/Y332G mutant against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/S287G/ A328W/Y332G mutant has a remarkably improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)-cocaine.

MD simulations. As with the A199S/A328W/Y332G 20 mutant, when performing any MD simulation on a transition state, in principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface.

The initial BChE structures used in the MD simulations were prepared based on our previous MD simulation as above with the prior mutant and the prereactive BChE-(–)-cocaine complex (ES) started from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1 POP).

The general procedure for carrying out the MD simulations in water is essentially the same as that used in the computational studies for mutant A199S/A328W/Y332G (mutant 1). Site-directed mutagenesis of human BChE cDNA was performed as described before.

The MD simulation in water was performed as described above, on this mutant. Depicted in FIG. 6 are plots of four important H . . . O distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain in A199S/S287G/A328W/Y332G BChE (mutant 3). RMSD represents the root-mean-square deviation (in Å) of the simulated positions of the protein backbone atoms from those in the initial structure.

The H...O distances in the simulated TS1 structures for wild-type BChE and its three mutants are summarized in Table 4. The H...O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 4 and FIG. 6. D4 in Table 4 and FIG. 6 refers to the H...O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/S287G/A328W/Y332G mutant.

TABLE 4

Summary of the MD-simulated key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (–)-cocaine benzoyl ester in the first transition state

(TS1)

		Dista				
Transition State		D1	D2	D3	D4	Total HBE^{b}
TS1 structure for (-)-cocaine	Average	4.59	2.91	1.92		-5.5 (-4.6)
hydrolysis catalyzed by	Maximum	5.73	4.14	2.35		
wild-type BChE	Minimum	3.35	1.97	1.61		
	Fluctuation	0.35	0.35	0.12		
TS1 structure for (-)-cocaine	Average	3.62	2.35	1.95		-6.2 (-4.9)
hydrolysis catalyzed by	Maximum	4.35	3.37	3.02		
A328W/Y332A mutant of BChE	Minimum	2.92	1.78	1.61		
	Fluctuation	0.23	0.27	0.17		
TS1 structure for (-)-cocaine	Average	3.60	2.25	1.97		-6.4 (-5.0)
hydrolysis catalyzed by	Maximum	4.24	3.17	2.76		
A328W/Y332G mutant of BChE	Minimum	2.89	1.77	1.62		
	Fluctuation	0.23	0.24	0.17		
TS1 structure for (-)-cocaine	Average	4.39	2.60	2.01	1.76	-14.0 (-12.0)
hydrolysis catalyzed by	Maximum	5.72	4.42	2.68	2.50	
A199S/S287G/A328W/Y332G	Minimum	2.87	1.76	1.62	1.48	
mutant of BChE	Fluctuation	0.48	0.36	0.17	0.12	

^aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/ S287G/A328W/Y332G mutant.

^bThe total HBE value is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances.

As seen in Table 4, the simulated H . . . O distance D1 is always too long for the peptidic NH of G116 to form a N-H... O hydrogen bond with the carbonyl oxygen of (-)-cocaine in all of the simulated TS1 structures. In the simulated TS1 structure for wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N-H . . . O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H . . . O distance (D2) was 1.61 to 2.35 Å, with an average D2 value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N-H... O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; 55 the simulated H . . . O distance (D3) was 1.97 to 4.14 Å (the average D3 value: 2.91 Å). The average D2 and D3 values became 2.35 and 1.95 Å, respectively, in the simulated TS1 structure for the A328W/Y332A mutant. These distances suggest a slightly weaker N-H . . . O hydrogen bond with 60 A199, but a stronger N—H . . . O hydrogen bond with G117, in the simulated TS1 structure for the A328W/Y332A mutant that the corresponding N-H . . . O hydrogen bonds for the wild-type. The average D2 and D3 values (2.25 and 1.97 Å, respectively) in the simulated TS1 structure for the A328W/ 65 Y332G mutant are close to the corresponding distances for the A328W/Y332A mutant. The overall strength of the hydro-

gen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A or A328W/Y332G mutant.

However, the story for the simulated TS1 structure for the A199S/S287G/A328W/Y332G mutant was remarkably different. As one can see from Scheme 5, FIG. 6, and Table 4, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an O-H ... O hydrogen bond, in addition to the two N-H ... O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H . . . O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.60, 2.01, and 1.76 Å, respectively. Due to the additional O-H . . . O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/S287G/A328W/Y332G BChE should be significantly stronger than that of wild-type, A328W/Y332A, and A328W/Y332G BChE's.



Scheme 5. Schematic representation of the transition-state structure for first reaction step for (-)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H... O distance was estimated by using the empirical HBE equa- 30 tion implemented in AutoDock 3.0 program suite of (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; 40 Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated 45 structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 $_{50}$ BChE for (-)-cocaine hydrolysis was reported to be ~8.6×10⁶ structure is also listed in Table 4.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H ... O distance. As seen in Table 4, the total hydrogen-bonding energies (i.e., -4.6, -4.9, -5.0, and -12.0 kcal/mol for the wild-type, A328W/Y332A, 55 A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, -6.4, and -14.0 kcal/mol) estimated in the aforementioned way. However, the 60 two sets of total HBE values are qualitatively consistent with each other in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbo- 65 nyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/S287G/A328W/Y332G BChE

is significantly higher than that for wild-type, A328W/ Y332A, and A328W/Y332G BChE's.

Catalytic activity. The computational results discussed above provides evidence that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/S287G/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A or A328W/Y332G mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature of Sun et al and Hamza et al also indicates that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This suggests a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A, A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a higher catalytic activity than A328W/ Y332A or A328W/Y332G BChE for (-)-cocaine hydrolysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A M min⁻, which is ~9.4 times of the k_{cat}/K_M value (~9.1×10⁵ M min⁻) of wild-type BChE for (-)-cocaine hydrolysis. The catalytic efficiency of A328W/Y332G BChE was found to be slightly higher than that of A328W/Y332A BChE for (-)cocaine hydrolysis. To examine the theoretical prediction of the higher catalytic activity for A199S/S287G/A328W/ Y332G BChE, the A328W/Y332A and A199S/S287G/ A328W/Y332G mutants of BChE were produced as previously discussed through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/S287G/A328W/Y332G BChE's to that of the wildtype for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the k_{cat}/K_M value

TS1

of A328W/Y332A BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of 5 the k_{cat}/K_M value of A199S/S287G/A328W/Y332G BChE to the k_{cat}/K_M value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be ~50.6. These data indicate that the ratio of the k_{cat}/K_M value of A199S/S287G/A328W/ Y332G BChE to the k_{cat}/K_M value of wild-type BChE for 10 (-)-cocaine hydrolysis should be ~50.6×8.6=~435 or ~50.6× 9.4=~476. Thus, A199S/S287G/A328W/Y332G BChE has a ~(456±41)-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/S287G/A328W/ Y332G BChE has a k_{cat}/K_{M} value of ~(4.15±0.37)×10⁸ M 15 \min^{-1} for (–)-cocaine hydrolysis. The catalytic efficiency of A199S/S287G/A328W/Y332G BChE against (-)-cocaine is much higher than that of AME-359 (i.e., F227A/S287G/ A328W/Y332M BChE, k_{cat}/K_{M} =3.1×10⁷ M min⁻, whose catalytic efficiency against (-)-cocaine is the highest within 20 all of the previously reported BChE mutants) which has a ~34-fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE.

By using the designed A199S/S287G/A328W/Y332G BChE as an exogenous enzyme in human, when the concen- 25 tration of this mutant is kept the same as that of the wild-type BChE in plasma, the half-life time of (–)-cocaine in plasma should be reduced from the ~45-90 min to only ~6-12 seconds, considerably shorter than the time required for cocaine crossing the blood-brain barrier to reach CNS. Hence, the 30 outcome of this study could eventually result in a valuable, efficient anti-cocaine medication.

44

Conclusion. The transition-state simulations demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)cocaine hydrolysis catalyzed by the wild-type BChE and other BChE mutants simulated. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a significantly lower energy barrier for the chemical reaction process and, therefore, a significantly higher catalytic efficiency (k_{cat}/K_M) for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a ~(456±41)-fold improved catalytic efficiency for A199S/S287G/A328W/Y332G BChE against (-)cocaine compared to the wild-type BChE. The k_{car}/K_{M} value determined for A199S/S287G/A328W/Y332G BChE is much higher than the k_{cat}/K_M value for AME-359 (i.e., F227A/S287G/A328W/Y332M BChE, whose catalytic efficiency against (-)-cocaine is the highest within all of the BChE mutants reported previously in literature) which has a ~34-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type BChE. The outcome of this study provides evidence that the transition-state simulation is a novel and unique approach for rational enzyme redesign and drug discovery.

Although the invention has been described in detail with respect to preferred embodiments thereof, it will be apparent that the invention is capable of numerous modifications and variations, apparent to those skilled in the art, without departing from the spirit and scope of the invention.

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 30
<210> SEQ ID NO 1
<211> LENGTH: 1722
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-1 mutant A199S/A328W/Y332G of Human
      butyrylcholinesterase (BChE)
<400> SEQUENCE: 1
qaaqatqaca tcataattqc aacaaaqaat qqaaaaqtca qaqqqatqaa cttqacaqtt
                                                                       60
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga
                                                                      120
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa
                                                                      180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag
                                                                      240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca
                                                                      300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact
                                                                      360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt
                                                                      420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct
                                                                      480
gaggeteeag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa
                                                                      540
aatataqcaq cctttqqtqq aaatcctaaa aqtqtaactc tctttqqaqa aaqttccqqa
                                                                      600
gcagetteag ttageetgea tttgetttet eetggaagee atteattgtt eaceagagee
                                                                      660
                                                                      720
attetgeaaa gtggtteett taatgeteet tggggeggtaa catetettta tgaagetagg
```

-continued

aaca atca																		
atca	agaad	gt t	gaad	cttaç	gc ta	aatt	gact	: ggt	tgct	cta	gaga	agaat	ga g	gacto	gaaat	a	780	D
	aagto	gtc t	taga	aaata	ia ag	gatco	cccaa	a gaa	aatto	ttc	tgaa	atgaa	igc a	attt	gttgt	с	840	D
ccct	catgo	gga d	etect	ttgt	c aç	gtaaa	acttt	: ggt	cccga	ccg	tgga	atggt	:ga t	ttt	ctcac	t	900)
gaca	atgco	ag a	acata	attad	et te	gaact	tgga	a caa	attta	aaa	aaad	cccaç	yat t	ttg	gtggg	t	96(D
gtta	aataa	ag a	atgaa	aggga	ac at	ggtt	ttta	a gto	cggtg	gtg	ctco	ctggo	ett d	cagea	aaaga	t	1020	þ
aaca	aataç	gta t	cata	aacta	ag aa	aaaga	aattt	caç	ggaag	gtt	taaa	aaata	att t	ttt	ccagg	a	1080	D
gtga	agtga	igt t	tgga	aaago	ja at	ccat	cctt	ttt	catt	aca	caga	actgo	ggt a	agato	gatca	g	1140	D
agad	cctga	aa a	actad	ccgt	ja go	geett	gggt	: gat	gttg	ttg	aaa	attat	aa t	ttca	atatg	с	1200)
cctç	geett	gg a	agtto	cacca	aa ga	aagtt	ctca	a gaa	atggg	Igaa	ataa	atgeo	ctt t	ttct	acta	t	1260	D
tttç	gaaca	acc g	gatco	etcca	aa a	ettec	gtgg	g cca	agaat	gga	tggg	gagto	yat ç	gcato	ggcta	t	1320	D
gaaa	attga	at t	tgto	ettt	gg t≀	taco	ctcto	g gaa	aagaa	gag	ataa	attac	cac a	aaaaq	geega	g	1380	D
gaaa	attt	ga g	gtaga	atcca	at aq	gtgaa	acgo	g tgg	ggcaa	att	ttgo	caaaa	ata t	ggga	aatcc	a	1440	D
aato	gagad	etc a	agaad	caata	ag ca	acaag	getge	g cct	gtct	tca	aaag	gcact	:ga a	acaaa	aata	t	1500	D
ctaa	acctt	ga a	ataca	agagt	c aa	acaac	gaata	a atg	gacga	aac	taco	gtgct	ca a	acaat	gtcg	a	1560	D
ttct	ggad	at o	catt	ttto	c aa	aaagt	ctto	g gaa	aatga	cag	gaaa	atatt	:ga t	gaaq	gcaga	a	1620	D
tggg	gagto	gga a	aagca	aggat	t co	cate	getge	g aad	caatt	aca	tgat	ggad	etg g	gaaaa	aatca	a	1680	D
ttta	aacga	itt a	acact	agea	aa ga	aaaga	aaagt	tgt	gtgg	gtc	tc						1722	2
<211 <212 <213 <220 <223	L> LE 2> T) 3> OF 0> FE 3> O] se	ENGTH PE: RGAN EATUH CHER equer	H: 5 PRT ISM: RE: INFO nce T	74 Art: DRMA nodij	lfic: TION Tied	ial : 14- BChE	-1 mu 2	ıtant	: (A1	.995,	/A328	3W/Y3	32G)	am:	lnio	acid	đ	
<400)> SE	QUEI	ICE :	2														
<400 Glu 1)> 2E Yab	equei Asp	NCE: Ile	2 Ile 5	Ile	Ala	Thr	Lys	Asn 10	Gly	ГЛа	Val	Arg	Gly 15	Met			
<400 Glu 1 Asn	D> SE Asp Leu	EQUEI Asp Thr	NCE: Ile Val 20	2 Ile 5 Phe	Ile Gly	Ala Gly	Thr Thr	Lys Val 25	Asn 10 Thr	Gly Ala	Lys Phe	Val Leu	Arg Gly 30	Gly 15 Ile	Met Pro			
<400 Glu 1 Asn Tyr	D> SE Asp Leu Ala	QUE Asp Thr Gln 35	NCE: Ile Val 20 Pro	2 Ile 5 Phe Pro	Ile Gly Leu	Ala Gly Gly	Thr Thr Arg 40	Lys Val 25 Leu	Asn 10 Thr Arg	Gly Ala Phe	Lys Phe Lys	Val Leu Lys 45	Arg Gly 30 Pro	Gly 15 Ile Gln	Met Pro Ser			
<400 Glu 1 Asn Tyr Leu	D> SE Asp Leu Ala Thr 50	Asp Thr Gln 35 Lys	NCE: Ile Val 20 Pro Trp	2 5 Phe Pro Ser	Ile Gly Leu Asp	Ala Gly Gly Ile 55	Thr Thr Arg 40 Trp	Lys Val 25 Leu Asn	Asn 10 Thr Arg Ala	Gly Ala Phe Thr	Lys Phe Lys Lys 60	Val Leu Lys 45 Tyr	Arg Gly 30 Pro Ala	Gly 15 Ile Gln Asn	Met Pro Ser Ser			
<400 Glu 1 Asn Tyr Leu Cys 65	D> SE Asp Leu Ala Thr 50 Cys	Asp Thr Gln 35 Lys Gln	NCE: Ile Val 20 Pro Trp Asn	2 Ile 5 Phe Pro Ser Ile	Ile Gly Leu Asp Asp 70	Ala Gly Gly Ile 55 Gln	Thr Thr Arg 40 Trp Ser	Lys Val 25 Leu Asn Phe	Asn 10 Thr Arg Ala Pro	Gly Ala Phe Thr Gly 75	Lys Phe Lys 60 Phe	Val Leu Lys 45 Tyr His	Arg Gly 30 Pro Ala Gly	Gly 15 Ile Gln Asn Ser	Met Pro Ser Ser Glu 80			
<400 Glu 1 Asn Tyr Leu Cys 65 Met	D> SE Asp Leu Ala Thr 50 Cys Trp	QUE Asp Thr Gln 35 Lys Gln Asn	VCE: Ile Val 20 Pro Trp Asn Pro	2 Jle 5 Phe Ser Ile Asn 85	Ile Gly Leu Asp 70 Thr	Ala Gly Gly Ile 55 Gln Asp	Thr Thr Arg 40 Trp Ser Leu	Lys Val 25 Leu Asn Phe Ser	Asn 10 Thr Arg Ala Pro Glu 90	Gly Ala Phe Thr Gly 75 Asp	Lys Phe Lys 60 Phe Cys	Val Leu Lys 45 Tyr His Leu	Arg Gly 30 Pro Ala Gly Tyr	Gly 15 Gln Asn Ser Leu 95	Met Pro Ser Ser Glu 80 Asn			
<400 Glu 1 Asn Tyr Leu Cys 65 Met Val	<pre>>> SE Asp Leu Ala Thr 50 Cys Trp Trp</pre>	QUE Asp Thr Gln 35 Lys Gln Asn Ile	NCE: Ile Val 20 Pro Trp Asn Pro Pro 100	2 Ile 5 Pro Ser Ile Asn 85 Ala	Ile Gly Leu Asp 70 Thr Pro	Ala Gly Gly Ile 55 Gln Asp Lys	Thr Thr Arg 40 Trp Ser Leu Pro	Lys Val 25 Leu Asn Phe Ser Lys 105	Asn 10 Thr Arg Ala Pro Glu 90 Asn	Gly Ala Phe Thr Gly 75 Asp Ala	Lys Phe Lys 60 Phe Cys Thr	Val Leu Lys 45 Tyr His Leu Val	Arg Gly 30 Pro Ala Gly Tyr Leu 110	Gly 15 Gln Asn Ser Leu 95 Ile	Met Pro Ser Ser Glu 80 Asn Trp			
<400 Glu 1 Asn Tyr Leu Cys 65 Met Val Ile	<pre>D> SE Asp Leu Ala Thr 50 Cys Trp Trp Tyr</pre>	QUE Asp Thr Gln 35 Lys Gln Asn Ile Gly 115	NCE: Ile Val 20 Pro Trp Asn Pro 100 Gly	2 Jle 5 Phe Ser Jle Asn 85 Ala Gly	Ile Gly Leu Asp 70 Thr Pro Phe	Ala Gly Gly Ile 55 Gln Lys Gln	Thr Thr Arg 40 Trp Ser Leu Pro Thr 120	Lys Val 25 Leu Asn Phe Ser Lys 105 Gly	Asn 10 Thr Arg Ala Pro Glu 90 Asn Thr	Gly Ala Phe Thr Gly 75 Asp Ala Ser	Lys Phe Lys 60 Phe Cys Thr Ser	Val Leu Lys 45 Tyr His Leu Val Leu 125	Arg Gly 30 Pro Ala Gly Tyr Leu 110 His	Gly 15 Ile Gln Asn Ser Leu 95 Ile Val	Met Pro Ser Ser Glu 80 Asn Trp Tyr			
<400 Glu 1 Asn Tyr Leu Cys 65 Met Val Ile Asp	<pre>>> SE Asp Leu Ala Thr 50 Cys Trp Trp Tyr Gly 130</pre>	QUE Asp Thr Gln Js Gln Asn Ile Gly 115 Lys	NCE: Ile Val 20 Pro Trp Asn Pro Pro 100 Gly Phe	2 Jle Phe Ser Ile Asn 85 Ala Gly Leu	Ile Gly Leu Asp 70 Thr Pro Phe Ala	Ala Gly Gly Ile 55 Gln Lys Gln Arg 135	Thr Thr Arg 40 Trp Ser Leu Pro Thr 120 Val	Lys Val 25 Leu Asn Phe Ser Lys 105 Gly Glu	Asn 10 Thr Arg Ala Pro Glu 90 Asn Thr Arg	Gly Ala Phe Thr Gly 75 Asp Ala Ser Val	Lys Phe Lys 60 Phe Cys Thr Ser Ile 140	Val Leu 45 Tyr His Leu Val Leu 125 Val	Arg Gly 30 Pro Ala Gly Tyr Leu 110 His Val	Gly 15 Ile Gln Asn Ser Leu 95 Ile Val Ser	Met Pro Ser Ser Glu 80 Asn Trp Tyr Met			
<400 Glu 1 Asn Tyr Leu Cys 65 Met Val Ile Asp Asn 145	<pre>>> SE Asp Leu Ala Thr 50 Cys Trp Typ Typ Gly 130 Typ</pre>	QUEN Asp Thr Gln 35 Lys Gln Asn Ile Gly 115 Lys Arg	NCE: Ile Val 20 Pro Trp Asn Pro 100 Gly Phe Val	2 Jle Phe Ser Ile Asn 85 Ala Gly Leu Gly	Ile Gly Leu Asp 70 Thr Pro Phe Ala Ala	Ala Gly Gly Ile 55 Gln Asp Lys Gln Arg 135 Leu	Thr Thr Arg 40 Trp Ser Leu Pro Thr 120 Val Gly	Lys Val 25 Leu Asn Phe Ser Lys Gly Glu Phe	Asn 10 Thr Arg Ala Pro Glu 90 Asn Thr Arg Leu	Gly Ala Phe Thr Gly 75 Asp Ala Ser Val Ala 155	Lys Phe Lys 60 Phe Cys Thr Ser Ile 140 Leu	Val Leu Lys 45 Tyr His Leu Leu Val Leu 125 Val Pro	Arg Gly 30 Pro Ala Gly Tyr Leu 110 His Val Gly	Gly 15 Gln Asn Ser Leu 95 Ile Val Ser Asn	Met Pro Ser Ser Glu 80 Asn Trp Tyr Tyr Met Pro 160			

Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Phe	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Сүз	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	Lys	Cys	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Ser	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	ГЛа	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Aab	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	ГÀа	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lya	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr
Lys	Leu	Arg 515	Ala	Gln	Gln	Сүз	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	Lys
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560
Phe	Asn	Asp	Tyr	Thr 565	Ser	Lys	Lys	Glu	Ser 570	Суз	Val	Gly	Leu		

<210> SEQ ID NO 3 <211> LENGTH: 1125 <212> TYPE: DNA

<213> ORGANISM: Artificial <220> FEATURE:

<223> OTHER INFORMATION: truncated 14-1 (A199S/A328/Y332G) nucleic Acid Sequence for modified BChE corresponding to a.a. residues 68-442

<400> SEQUE	ENCE: 3					
aacatagatc	aaagttttcc	aggetteeat	ggatcagaga	tgtggaaccc	aaacactgac	60
ctcagtgaag	actgtttata	tctaaatgta	tggattccag	cacctaaacc	aaaaatgcc	120
actgtattga	tatggattta	tggtggtggt	tttcaaactg	gaacatcatc	tttacatgtt	180
tatgatggca	agtttctggc	tcgggttgaa	agagttattg	tagtgtcaat	gaactatagg	240
gtgggtgccc	taggattett	agctttgcca	ggaaatcctg	aggctccagg	gaacatgggt	300
ttatttgatc	aacagttggc	tcttcagtgg	gttcaaaaaa	atatagcagc	ctttggtgga	360
aatcctaaaa	gtgtaactct	ctttggagaa	agttccggag	cagcttcagt	tagcctgcat	420
ttgetttete	ctggaagcca	ttcattgttc	accagagcca	ttctgcaaag	tggttccttt	480
aatgctcctt	gggcggtaac	atctctttat	gaagctagga	acagaacgtt	gaacttagct	540
aaattgactg	gttgctctag	agagaatgag	actgaaataa	tcaagtgtct	tagaaataaa	600
gatecceaag	aaattcttct	gaatgaagca	tttgttgtcc	cctatgggac	tcctttgtca	660
gtaaactttg	gtccgaccgt	ggatggtgat	tttctcactg	acatgccaga	catattactt	720
gaacttggac	aatttaaaaa	aacccagatt	ttggtgggtg	ttaataaaga	tgaagggaca	780
tggtttttag	tcggtggtgc	tcctggcttc	agcaaagata	acaatagtat	cataactaga	840
aaagaatttc	aggaaggttt	aaaaatattt	tttccaggag	tgagtgagtt	tggaaaggaa	900
tccatccttt	ttcattacac	agactgggta	gatgatcaga	gacctgaaaa	ctaccgtgag	960
gccttgggtg	atgttgttgg	ggattataat	ttcatatgcc	ctgccttgga	gttcaccaag	1020
aagtteteag	aatggggaaa	taatgccttt	ttctactatt	ttgaacaccg	atcctccaaa	1080
cttccgtggc	cagaatggat	gggagtgatg	catggctatg	aaatt		1125
<210> SEQ 1 <211> LENGT <212> TYPE:	ID NO 4 IH: 375 : PRT					

<213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: truncated 14-1 mutant (A199S/A328/Y332G) amino acid sequence of modified BChE <400> SEQUENCE: 4 Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met $\operatorname{Trp}\nolimits\operatorname{Asn}$ 1 5 10 15 Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile20 25 30 Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 40 35 45 Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 55 60 50 Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 70 75 80 65 Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 85 90 95 Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 105 100 110 Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe

120

-continued

Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro	
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Phe 160	
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr	
Leu	Asn	Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu	
Ile	Ile	Lys 195	Суз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn	
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Ser 220	Val	Asn	Phe	Gly	
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240	
Glu	Leu	Gly	Gln	Phe 245	Lys	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys	
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys	
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys	
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe	
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320	
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Aab	Tyr	Asn 330	Phe	Ile	Cys	Pro	Ala 335	Leu	
Glu	Phe	Thr	Lys 340	Lys	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr	
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly	
Val	Met 370	His	Gly	Tyr	Glu	Ile 375										
<210 <211 <212 <213 <220 <223)> SH 1> LH 2> TY 3> OF 3> OF 3> OT ac	EQ II ENGTH (PE: RGAN] EATUF THER cid a) NO H: 96 DNA ISM: RE: INF(seque	5 56 Art: DRMA ence	lfic: FION: cori	ial : 14- cespo	-1 mu ondir	itant ng to	: (A: b a.a	1995, a. re	/A328	BW/Y:	332G) 117-4) BCł 138	1E nucl	.eic
<400)> SE	IQUE	ICE :	5												
ggtt	ttca	aaa d	etgga	acat	c at	ctt	cacat	t gtt	tato	gatg	gcaa	agtti	cct (ggeto	gggtt	
gaaa	igagi	ata u	rtgia	agugi	rc ac	ngaa	acta	r age	Jgrgg	Jgrð	ate	agga	att o	aacta	rttcag	-
tqq	, gener	aaa a	aaaat	cata	qc ac	accti	tqqt	c qqa	aato	ccta	aaa	atqta	aac t	cctct	ttqqa	2
gaaa	agtto	ccg g	gagca	ageti	c ag	gttag	geete	g cat	ttg	ttt	ctco	tgga	aag (ccatt	cattg	3
ttca	accag	gag d	ccatt	ctg	ca aa	agtgo	gttco	e ttt	aato	gctc	ctt	gggcá	ggt a	aacat	ctctt	3
tato	jaago	cta g	ggaad	cagaa	ac gt	tgaa	actta	a get	caaat	tga	ctg	gttg	ctc 1	cagag	gagaat	4
gaga	actga	aaa t	caato	caagt	g to	cttaç	gaaat	c aaa	agato	cccc	aaga	aatt	cct 1	cctga	aatgaa	4
gcat	ttgt	tg t	cccc	ctato	gg ga	actco	cttt	g tca	agtaa	aact	ttg	gtcc	gac (cgtgg	gatggt	9
gatt	ttct	ca d	ctgad	catgo	cc aç	gacat	tatta	a ctt	gaad	cttg	gaca	aatti	caa a	aaaaa	acccag	e

-continued

attttgg	tgg 🤅	gtgti	taata	aa aq	gatga	aaggo	g aca	atggt	ttt	tagi	ccggt	gg i	geto	cctggc
ttcagca	aag a	ataa	caata	ag ta	atcat	caact	aga	aaaaq	gaat	ttca	aggaa	agg 1	ttaa	aaata
tttttc	cag g	gagto	gagto	ga gt	ttg	gaaaq	g gaa	atcca	atcc	ttti	tcat	ta	cacaç	gactgg
gtagatg	atc a	agaga	accto	ga aa	aacta	accgt	: gao	ggaat	tgg	gtga	atgti	tgt 1	gggg	gattat
aatttca	tat 🤉	geeet	tgcct	t g	gagti	ccaco	aaq	gaagt	tct	caga	aatgo	ada 4	aaata	aatgcc
tttttct	act a	attt	tgaad	ca co	cgato	cctco	c aaa	actto	ccgt	ggco	cagaa	atg g	gatgo	ggagtg
atgcat														
<pre>atgcat <210> SEQ ID NO 6 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE a.a. residues 117-438 <400> SEQUENCE: 6</pre>														
<400> S	EQUEI	NCE :	6											
Gly Phe 1	Gln	Thr	Gly 5	Thr	Ser	Ser	Leu	His 10	Val	Tyr	Asp	Gly	Lys 15	Phe
Leu Ala	Arg	Val 20	Glu	Arg	Val	Ile	Val 25	Val	Ser	Met	Asn	Tyr 30	Arg	Val
Gly Ala	Leu 35	Gly	Phe	Leu	Ala	Leu 40	Pro	Gly	Asn	Pro	Glu 45	Ala	Pro	Gly
Asn Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Lys
Asn Ile 65	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80
Glu Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly
Ser His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Phe	Asn
Ala Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu
Asn Leu 130	Ala	Lys	Leu	Thr	Gly 135	Суз	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile
Ile Lys 145	Сүз	Leu	Arg	Asn 150	Lys	Aab	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160
Ala Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Ser	Val	Asn	Phe	Gly 175	Pro
Thr Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu
Leu Gly	Gln 195	Phe	Lys	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp
Glu Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp
Asn Asn 225	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240
Phe Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His
Tyr Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala
Leu Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Суз	Pro 285	Ala	Leu	Glu

Phe	Thr 290	Lys	Lys	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr		
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320		
Met	His																
<210 <211 <212 <213 <220 <223	 > SI > LI > TY > OF > FI > OT ft 	EQ II ENGTH (PE: RGANI EATUH FHER 111 1	D NO H: 1 DNA ISM: RE: INF(nucle	7 722 Arti DRMA1 ⊇ic a	fic: Non Sign	ial : 14- sequ	2 mu ience	itant	: (A1	.995/	′F227	7A/A3	328W,	/¥332	2G) 1	3ChE,	
<400	> SH	EQUEI	NCE :	7													
gaag	latga	aca t	tcata	aatto	jc aa	acaaa	igaat	gga	aaag	ıtca	gago	ggato	jaa (cttga	acag	tt	60
tttg	gtgg	gca d	cggta	aacag	jc ct	ttct	tgga	att	ccct	atg	caca	ageca	acc 1	tcttç	ggtag	ga	120
ctto	gatt	ca a	aaaaq	gecad	a gt	cctct	gaco	aag	gtggt	ctg	atat	ttgg	jaa 1	tgcca	acaa	aa	180
tatg	caaa	att d	cttgo	ctgto	a ga	aacat	agat	caa	agtt	ttc	cago	gette	ca i	tggat	caga	ag	240
atgt	ggaa	acc d	caaad	cacto	ja co	ctcaç	ytgaa	gad	tgtt	tat	atct	aaat	gt a	atgga	attco	ca	300
gcac	ctaa	aac d	caaaa	aaatg	jc ca	actgt	attg	ata	atgga	ittt	atgo	gtggt	gg t	tttt	caaa	ct	360
ggaa	cato	cat d	cttta	acato	jt ti	tatga	atggo	aag	gtttc	tgg	ctcg	gggtt	ga a	aagag	gtta	tt	420
gtag	ıtgto	caa t	tgaad	ctata	ıg ge	gtggg	gtgcc	cta	ıggat	tct	tago	tttg	jcc i	aggaa	aatco	ct	480
gagg	lctco	cag g	ggaad	catgo	ıg ti	tatt	tgat	caa	acagt	tgg	ctct	tcag	gtg g	ggtto	caaa	aa	540
aata	tago	cag d	cctt	ggtg	jg aa	aatco	taaa	agt	gtaa	ictc	tctt	tgga	aga a	aagtt	ceeg	ga	600
gcag	ctto	cag t	tago	cctgo	a ti	tget	ttct	cct	ggaa	ıgcc	atto	atte	gtt (cacca	agago	cc	660
atto	tgca	aaa q	gtggt	tccc	jc ta	aatgo	etcct	tgg	lacac	Itaa	cato	etett	ta	tgaaq	gcta	3g	720
aaca	gaad	cgt t	tgaad	ettag	jc ta	aaatt	gact	ggt	tgct	cta	gaga	agaat	ga g	gacto	gaaa	ta	780
atca	agto	gtc t	taga	aaata	ia aq	gatco	ccaa	gaa	atto	ttc	tgaa	atgaa	agc a	atttç	gttgi	tc	840
ccct	atgo	gga d	ctcct	ttgt	c aq	gtaaa	acttt	ggt	ccga	ıccg	tgga	atggt	:ga 1	tttt	ctca	ct	900
gaca	tgco	cag a	acata	attac	t tạ	gaact	tgga	caa	itta	iaaa	aaad	ccaç	gat 1	tttgg	gtgg	gt	960
gtta	ataa	aag a	atgaa	aggga	ic at	ggtt	ttta	gto	ggtg	ıgtg	ctco	tggo	ett (cagca	aaaga	at	1020
aaca	ataç	gta t	tcata	aacta	ıg aa	aaaga	attt	caç	gaag	gtt	taaa	aata	att 1	tttt	ccage	ga	1080
gtga	igtga	igt t	tgga	aaago	ja at	cccat	cctt	ttt	catt	aca	caga	actgo	gt a	agato	gatca	ag	1140
agac	ctga	aaa a	actad	ccgte	ja go	geett	gggt	gat	gttg	ıttg	ggga	attat	aa 1	tttca	atat	gc	1200
cctg	lcctt	gg a	agtto	cacca	ia ga	aagtt	ctca	gaa	atggg	ıgaa	ataa	atgeo	tt i	tttct	cacta	at	1260
tttg	laaca	acc ç	gatco	ctcca	ia a	cttco	gtgg	l cca	igaat	gga	tggg	gagto	gat o	gcato	ggcta	at	1320
gaaa	ittga	aat t	ttgt	stttg	ıg tı	taco	etetg	gaa	agaa	ıgag	ataa	attac	cac a	aaaaq	geega	ag	1380
gaaa	ittt	:ga ç	gtaga	atcca	it aq	gtgaa	acgg	ı tgg	gcaa	att	ttgo	caaaa	ata 1	tggga	aatco	ca	1440
aatg	agad	ctc a	agaad	caata	ıg ca	acaaç	gctgg	r cct	gtct	tca	aaaq	gcact	ga a	acaaa	aaata	at	1500
ctaa	cctt	:ga a	ataca	agagt	c aa	acaaç	jaata	atg	jacga	iaac	tace	gtgct	ca a	acaat	gtc	ga	1560
ttct	ggad	cat d	catt	tttc	c aa	aaagt	cttg	ı gaa	atga	ıcag	gaaa	atatt	ga i	tgaag	gcaga	aa	1620
tggg	agto	gga a	aagca	aggat	t co	cates	getgg	aac	aatt	aca	tgat	ggad	tg g	gaaaa	aatca	aa	1680
ttta	acga	att a	acact	cagea	ia ga	aaaga	aagt	tgt	gtgg	gtc	tc						1722

<210 <211 <211 <211 <211 <220 <223	0> SH L> LH 2> TY 3> OH 0> FH 3> OT an	EQ II ENGTH YPE: RGANI EATUH FHER nino	D NO H: 5' PRT ISM: RE: INF(acid	8 74 Art: DRMA d sec	ific: TION quenc	ial : 14· ce	-2 mi	utant	: (A:	1995,	/F22	7A/A:	328W,	/ ¥332	2G),	full
<400	D> SH	EQUEI	ICE :	8												
Glu 1	Asp	Asb	Ile	Ile 5	Ile	Ala	Thr	Lys	Asn 10	Gly	Lys	Val	Arg	Gly 15	Met	
Asn	Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro	
Tyr	Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser	
Leu	Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys 60	Tyr	Ala	Asn	Ser	
Суз 65	Cys	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80	
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Суз	Leu	Tyr	Leu 95	Asn	
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp	
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr	
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met	
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160	
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln	
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val	
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu	
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser	
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240	
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Суз	Ser	Arg	Glu 255	Asn	
Glu	Thr	Glu	Ile 260	Ile	Lys	Суз	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile	
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Ser	Val	
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp	
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320	
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly	
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu	
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser	

-continued

												0011	C 111	ucu	
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr
Lys	Leu	Arg 515	Ala	Gln	Gln	Суз	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	Lys
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560
Phe	Asn	Asp	Tyr	Thr 565	Ser	ГЛа	Lys	Glu	Ser 570	Суз	Val	Gly	Leu		
<212 <213 <220 <223	2> T 3> OF 0> F 3> O 3> O nu	YPE: RGAN EATU THER LCLE	DNA ISM: RE: INF(ic a)	Art: DRMA cid s	ific: TION seque	ial : 14 ence	-2 mu for	ıtant a.a.	: (A: . re:	L99/] ∋idu∢	7227) 98 61	A/A3: 8-44:	28W/1 2	¥3220	G) BChE
<400)> SI	EQUEI	NCE :	9											
aaca	ataga	atc a	aaagi	ttt	cc ag	ggctt	ccat	gga	atcaç	gaga	tgt	ggaa	ccc a	aaaca	actgac
ctca	agtga	aag	actgi	ttat	ta to	ctaaa	atgta	a tgo	gatto	ccag	cac	ctaa	acc a	aaaaa	aatgcc
acto	gtati	:ga	tatg	gatti	ta to	ggtg	gtggt	ttt	caaa	actg	gaa	catca	atc 1	tttad	catgtt
tato	gatgo	gca a	agtti	cctg	gc to	cgggt	tgaa	a aga	agtta	attg	tagi	tgtca	aat q	gaact	tatagg
gtgg	ggtgo	ccc 1	tagga	attci	t ag	gcttt	geea	a gga	aaato	cctg	agg	ctcca	agg g	gaaca	atgggt
ttat	ttga	atc a	aacaq	gttg	gc to	cttca	agtgę	g gtt	caaa	aaaa	ata	tage	agc (cttt	ggtgga
aato	cctaa	aaa g	gtgta	aacto	ct ci	tttg	gagaa	a agt	tccç	ggag	cag	cttea	agt 1	tageo	ctgcat
ttgo	ettto	ctc (ctgga	aagco	ca ti	tcatt	gtt	c aco	cagao	gcca	ttci	tgca	aag 1	tggtt	ceget
aato	geteo	ett g	gggc	ggtaa	ac af	tetet	ttat	c gaa	ageta	agga	aca	gaaco	gtt q	gaact	taget
aaat	tgad	ctg o	gttg	ctcta	ag ag	gagaa	atga	g act	gaaa	ataa	tca	agtgi	tct 1	tagaa	aataaa
gato	cccca	aag	aaati	cctt	ct ga	aatga	aagca	a tti	gtto	gtcc	ccta	atgg	gac 1	tcctt	tgtca
gtaa	aactt	tg	gtcc	gacco	gt g	gatgo	gtgat	ttt	ctca	actg	acat	tgcca	aga (catat	tactt
gaad	cttgg	gac (aatti	caaaa	aa a	accca	agati	t ttç	ggtgg	ggtg	tta	ataa	aga 1	tgaaq	gggaca
tggt	ttti	ag i	tcggi	cggt	gc to	cctg	getto	c ago	caaaq	gata	aca	atagi	tat 🤇	cataa	actaga
aaaq	gaatt	tc	aggaa	aggti	t a	aaaat	att	ttt	ccaq	ggag	tga	gtga	gtt 1	tggaa	aaggaa

-continued

tcca	atcct	tt t	ttca	ttaca	ac aç	gacto	gggta	a gat	gato	caga	gac	ctga	aaa (ctaco	egtgag
gcct	tgg	gtg a	atgti	tgtt	aa aa	gatta	ataat	t t t	catat	gcc	ctg	cctt	gga 🤉	gttca	accaag
aagt	tete	cag a	aatgo	gggaa	aa ta	aatgo	ccttt	tt:	ctact	att	ttg	aaca	ccg a	atcct	ccaaa
ctto	ccgto	ggc (cagaa	atgga	at go	ggagi	tgato	g cat	gget	tatg	aaat	t			
<210 <211 <211 <211 <211 <220 <221	0> SI L> LI 2> T 3> OI 0> FI 3> O 3> O at	EQ II ENGTH YPE: RGANI EATUH FHER mino	D NO H: 3' PRT ISM: RE: INF(acid	10 75 Art: ORMA d sec	ific: TION quenc	ial : 14 ce fo	-2 mu or re	ıtant	: (A: 1es (1995, 58-44	/F22 [*] 42	7A/A:	328W,	/ ¥332	2G) BChE,
<400	D> SI	EQUEI	NCE :	10											
Asn 1	Ile	Asp	Gln	Ser 5	Phe	Pro	Gly	Phe	His 10	Gly	Ser	Glu	Met	Trp 15	Asn
Pro	Asn	Thr	Asp 20	Leu	Ser	Glu	Asp	Сув 25	Leu	Tyr	Leu	Asn	Val 30	Trp	Ile
Pro	Ala	Pro 35	Гла	Pro	Lys	Asn	Ala 40	Thr	Val	Leu	Ile	Trp 45	Ile	Tyr	Gly
Gly	Gly 50	Phe	Gln	Thr	Gly	Thr 55	Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys
Phe 65	Leu	Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80
Val	Gly	Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln
ГЛа	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	ГÀа	Ser	Val 125	Thr	Leu	Phe
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Ala 160
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr
Leu	Asn	Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu
Ile	Ile	Lys 195	Сүз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Ser 220	Val	Asn	Phe	Gly
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240
Glu	Leu	Gly	Gln	Phe 245	Lys	Гла	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys
Aab	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Гла
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320

-continued

Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 325 330 335 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 350 340 345 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 355 360 365 Val Met His Gly Tyr Glu Ile 370 375 <210> SEQ ID NO 11 <211> LENGTH: 966 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE nucleic acid sequence for residues 117-438 <400> SEQUENCE: 11 ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg ttcaccagag ccattetgea aagtggttee getaatgete ettgggeggt aacatetett tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat gagactgaaa taatcaagtg tettagaaat aaagateeee aagaaattet tetgaatgaa gcatttgttg tcccctatgg gactcctttg tcagtaaact ttggtccgac cgtggatggt gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag attttqqtqq qtqttaataa aqatqaaqqq acatqqtttt taqtcqqtqq tqctcctqqc ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg atqcat <210> SEQ ID NO 12 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-2 (A199S/F227A/A328W/Y332G) a.a residues 117-438 <400> SEQUENCE: 12 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 10 Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 25 Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 45 35 40 Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

-continued

	50					55					60				
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Ala	Asn
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu
Asn	Leu 130	Ala	Lys	Leu	Thr	Gly 135	Cys	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile
Ile 145	Lys	Сүз	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Ser	Val	Asn	Phe	Gly 175	Pro
Thr	Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu
Leu	Gly	Gln 195	Phe	Гла	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp
Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Суз	Pro 285	Ala	Leu	Glu
Phe	Thr 290	Lys	Lys	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320
Met	His														
<210 <211 <211 <211 <221 <220 <223	0> SI L> LI 2> T 3> OI 0> FI 3> O 1 3> O 1 n	EQ II ENGTI YPE: RGAN: EATUI FHER LCle:	D NO H: 1' DNA ISM: RE: INFO ic ao	13 722 Art: DRMA cid :	ific: TION seque	ial : 14- ence	-3 mu	ıtant	: (A:	1995,	/528'	7G/A:	328W,	/ ¥332	2G) BChE
<400	D> SI	EQUEI	ICE :	13											
gaaq	gatga	aca 1	cata	aatto	gc aa	acaaa	agaat	gga	aaaaq	gtca	gago	ggato	gaa (cttga	acagtt
tttç	ggtgg	gca (cggta	aaca	ge et	ttct	ttgga	a att	cccct	tatg	caca	ageea	acc t	cctt	ggtaga
ctto	cgatt	tca a	aaaa	gcca	ca gt	cctct	tgaco	c aaq	gtggt	ctg	atai	ttg	gaa 1	geea	acaaaa
tato	gcaaa	att (ettg	ctgt	ca ga	aacat	tagat	c caa	aagtt	ttc	cago	getto	cca 1	zggat	cagag
atgi	ggaa	acc (caaa	cact	ga co	ctcaç	gtgaa	a gao	ctgtt	tat	atci	caaat	:gt a	atgga	attcca
gcad	cctaa	aac (caaaa	aaat	ge ea	actgt	tattç	g ata	atgga	attt	atg	gtggi	cgg 1	ttt	caaact
ggaa	acato	cat (ttta	acat	gt ti	tatga	atggo	c aaq	gttto	ctgg	ctc	yggt I	cga a	aagaq	gttatt
gtaq	gtgto	caa 1	gaa	ctata	ag gé	gtggg	gtgco	c cta	aggat	tct	tago	ttt	gee a	aggaa	aatcct

-continued

gaggeteca	g ggaa	catgg	g ttta	tttga	t caa	acagt	tgg	ctct	tcag	tg	ggtto	caaaaa	540
aatatagca	g cctt	tggtgg	g aaat	cctaa	a agt	gtaa	actc	tctt	tgga	ga	aagtt	ccgga	600
gcagcttca	g ttag	cctgca	a tttg	ctttci	t cct	ggaa	agcc	atto	cattg	tt	cacca	agagcc	660
attctgcaa	a gtgg	ttcctt	taat	getee	t tgo	ggegg	gtaa	cato	ctctt	ta	tgaaq	gctagg	720
aacagaacg	tgaa	cttage	c taaa	ttgaci	t ggt	tgct	cta	gaga	agaat	ga	gacto	gaaata	780
atcaagtgt	c ttag	aaataa	a agat	cccca	a gaa	aatto	ette	tgaa	atgaa	gc	atttç	gttgtc	840
ccctatggg	a ctcc	tttggg	g tgta	aactt	t ggt	ccga	accg	tgga	atggt	ga	tttt	ctcact	900
gacatgcca	g acat	attact	t tgaa	cttgga	a caa	attta	aaaa	aaad	cccag	at	tttgg	ıtgggt	960
gttaataaa	g atga	agggad	c atgg	tttt	a gto	ggt	ggtg	ctco	ctggc	tt	cagca	aagat	1020
aacaatagt	a tcat	aactaç	g aaaa	gaatti	t caç	ggaag	ggtt	taaa	aaata	tt	tttt	cagga	1080
gtgagtgag	ttgg	aaagga	a atcc	atccti	t tti	catt	aca	caga	actgg	gt	agato	gatcag	1140
agacctgaa	a acta	ccgtga	a ggcc	ttgggi	t gat	gtto	gttg	ggga	attat	aa	tttca	atatgc	1200
cctgccttg	g agtt	caccaa	a gaag	ttctca	a gaa	atggg	ggaa	ataa	atgcc	tt	tttct	actat	1260
tttgaacac	c gatc	ctccaa	a actt	ccgtg	g cca	agaat	gga	tggg	gagtg	at	gcato	gctat	1320
gaaattgaa	ttgt	ctttgg	g ttta	cctct	g gaa	aagaa	agag	ataa	attac	ac	aaaag	jccgag	1380
gaaattttg	a gtag	atccat	agtg	aaacg	g tgo	ggcaa	att	ttgo	caaaa	ta	tggga	atcca	1440
aatgagact	c agaa	caataç	g caca	agctg	g oct	gtct	tca	aaaq	gcact	ga	acaaa	aatat	1500
ctaaccttg	a atac	agagto	c aaca	agaata	a atç	gacga	aac	taco	gtgct	ca	acaat	gtcga	1560
ttctggaca	catt	tttco	c aaaa	gtctt	g gaa	aatga	acag	gaaa	atatt	ga	tgaaq	jcagaa	1620
tgggagtgg	a aagc	aggatt	ccat	cgctg	g aad	caatt	aca	tgat	cggad	tg	gaaaa	atcaa	1680
tttaacgat	acac	tagcaa	a gaaa	gaaagi	t tgt	gtgg	ggtc	tc					1722
<210> SEQ <211> LEN <212> TYP <213> ORG <220> FEA <223> OTH ami:	ID NO GTH: 5 E: PRT ANISM: TURE: ER INF NO aci	14 74 Artii ORMATI d sequ	Eicial ION: 1 lence	4-3 m	utant	= (A1	1995,	/528	7G/A3	28W	/ ¥332	G) BCł	ъЕ
<400> SEQ	JENCE :	14											
Glu Asp A 1	ap Ile	Ile I 5	[le Al	a Thr	Lys	Asn 10	Gly	Lys	Val	Arg	Gly 15	Met	
Asn Leu T	nr Val 20	Phe (Gly Gl	y Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro	
Tyr Ala G 3	ln Pro 5	Pro I	Leu Gl	y Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser	
Leu Thr Ly 50	/s Trp	Ser A	Asp Il 55	e Trp	Asn	Ala	Thr	Lys 60	Tyr	Ala	Asn	Ser	
Суз Суз G 65	ln Asn	Ile <i>P</i>	Asp Gl 70	n Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80	
Met Trp A	an Pro	Asn 1 85	[hr As	p Leu	Ser	Glu 90	Asp	Сүз	Leu	Tyr	Leu 95	Asn	
Val Trp I	le Pro 100	Ala H	Pro Ly	s Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp	
Ile Tyr G 1	Ly Gly	Gly H	Phe Gl	n Thr	Gly	Thr	Ser	Ser	Leu	His	Val	Tyr	
	15			120					125				

-continued

Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Clu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln

-continued

Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570
<210> SEQ ID NO 15 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 68-442
<400> SEQUENCE: 15
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt 480
aatgeteett gggeggtaac atetettat gaagetagga acagaaegtt gaaettaget 540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 600
gatccccaag aaattettet gaatgaagea tttgttgtee eetatgggae teetttgggt 660
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 780
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020
aagtteteag aatggggaaa taatgeettt ttetaetatt ttgaacaeeg ateeteeaaa 1080
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125
<210> SEQ ID NO 16 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A1995/S287G/A328W/Y332G) BChE amino acid sequence for residues 68-442
<400> SEQUENCE: 16
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 1 5 10 15
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 20 25 30
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 35 40 45
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 50 55 60
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 65 70 75 80
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro

-continued

				85					90					95	
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln
Lys	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	Lys	Ser	Val 125	Thr	Leu	Phe
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Phe 160
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr
Leu	Asn	Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu
Ile	Ile	Lys 195	Сүз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Aab	Met 235	Pro	Asp	Ile	Leu	Leu 240
Glu	Leu	Gly	Gln	Phe 245	Lys	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Гла
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Гла
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Asp	Tyr	Asn 330	Phe	Ile	Сув	Pro	Ala 335	Leu
Glu	Phe	Thr	Lys 340	Lys	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly
Val	Met 370	His	Gly	Tyr	Glu	Ile 375									
<210 <212 <212 <212 <220 <222	D> SI L> LH 2> TY 3> OF D> FI 3> OT nu	EQ II ENGTH (PE: RGANI EATUH THER 1Clei	D NO H: 96 DNA ISM: RE: INFC ic ac	17 56 Art: DRMA: cid :	lfic: TION : Seque	ial : 14- ence	-3 mu for	ıtant amir	: (A1 10 ac	1995, cid 1	/S28 resid	7G/A: lues	328W/ 117-	/¥332 - 438	2G) BChE
< 400		COO FI		1/											
ggti	LTCA	iaa d	tgga	acat	.c at	CTT	acat	gtt	tato	jatg	gcaa	agtti	CC Q	geto	egggtt
gaaa	agagt	ta t	tgta	agtgi	c aa	atgaa	actat	age	ggtgg	ggtg	ccct	agga	att (ottag	getttg
taa	yyaad attaa	aut (yaq	-ater	no ag	19948	-taat	- aa	aat/	nct a	auda	acaç	ar s	- at at	ttaga
qaa	aqtta	cca c	aaa	aqcti	c au	attad	accta	a gya	tta	ttt	ctco	taa,	aad o	ccatt	cattq
ttca	accad	jag d	cati	cetgo	ca aa	agtgo	gttco	e ttt	aato	gete	ctto	jggco	ggt a	acat	ctett

US 7,731,957 B1

-continued

tatgaagcta	ggaacagaac	gttgaactta	gctaaattga	ctggttgctc	tagagagaat	420
gagactgaaa	taatcaagtg	tcttagaaat	aaagatcccc	aagaaattct	tctgaatgaa	480
gcatttgttg	tcccctatgg	gactcctttg	ggtgtaaact	ttggtccgac	cgtggatggt	540
gattttctca	ctgacatgcc	agacatatta	cttgaacttg	gacaatttaa	aaaaacccag	600
attttggtgg	gtgttaataa	agatgaaggg	acatggtttt	tagtcggtgg	tgeteetgge	660
ttcagcaaag	ataacaatag	tatcataact	agaaaagaat	ttcaggaagg	tttaaaaata	720
tttttccag	gagtgagtga	gtttggaaag	gaatccatcc	tttttcatta	cacagactgg	780
gtagatgatc	agagacctga	aaactaccgt	gaggcettgg	gtgatgttgt	tggggattat	840
aatttcatat	gccctgcctt	ggagttcacc	aagaagttct	cagaatgggg	aaataatgcc	900
tttttctact	attttgaaca	ccgatcctcc	aaacttccgt	ggccagaatg	gatgggagtg	960
atgcat						966

<210> SEQ ID NO 18 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438 <400> SEQUENCE: 18 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 35 40 45 Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 65 70 75 80 Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile Ile Lys Cys Leu Arg As
n Lys Asp Pro Gln Glu Ile Leu Leu As
n Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 200 205 Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His

-continued

245	250	255
Tyr Thr Asp Trp Val Asp Asp Gln 260	Arg Pro Glu Asn Tyr Arg 265 270	Glu Ala
Leu Gly Asp Val Val Gly Asp Tyr 275 280	Asn Phe Ile Cys Pro Ala 285	Leu Glu
Phe Thr Lys Lys Phe Ser Glu Trp 290 295	Gly Asn Asn Ala Phe Phe 300	Tyr Tyr
Phe Glu His Arg Ser Ser Lys Leu 305 310	Pro Trp Pro Glu Trp Met 315	Gly Val 320
Met His		
<210> SEQ ID NO 19 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 m BChE nucleic acid sequence	utant (A1995/F227A/S287G, e	/A328W/Y332G)
<400> SEQUENCE: 19		
gaagatgaca tcataattgc aacaaagaa	t ggaaaagtca gagggatgaa (cttgacagtt 60
tttggtggca cggtaacagc ctttcttgg	a attecetatg cacageeace t	ccttggtaga 120
cttcgattca aaaagccaca gtctctgac	c aagtggtctg atatttggaa t	cgccacaaaa 180
tatgcaaatt cttgctgtca gaacataga	t caaagttttc caggcttcca t	tggatcagag 240
atgtggaacc caaacactga cctcagtga	a gactgtttat atctaaatgt a	atggattcca 300
gcacctaaac caaaaaatgc cactgtatt	g atatggattt atggtggtgg t	tttcaaact 360
ggaacatcat ctttacatgt ttatgatgg	c aagtttctgg ctcgggttga a	aagagttatt 420
gtagtgtcaa tgaactatag ggtgggtgc	c ctaggattct tagctttgcc a	aggaaatcct 480
gaggeteeag ggaacatggg tttatttga	t caacagttgg ctcttcagtg q	ggttcaaaaa 540
aatatagcag cctttggtgg aaatcctaa	a agtgtaactc tctttggaga a	aagttccgga 600
gcagetteag ttageetgea tttgettte	t cctggaagcc attcattgtt d	caccagagcc 660
attetgeaaa gtggtteege taatgetee	t tgggcggtaa catctcttta t	tgaagctagg 720
aacagaacgt tgaacttagc taaattgac	t ggttgctcta gagagaatga g	gactgaaata 780
atcaagtgtc ttagaaataa agatcccca	a gaaattette tgaatgaage a	atttgttgtc 840
ccctatggga ctcctttggg tgtaaactt	t ggtccgaccg tggatggtga t	tttctcact 900
gacatgccag acatattact tgaacttgg	a caatttaaaa aaacccagat t	ttggtgggt 960
gttaataaag atgaagggac atggttttt	a gtcggtggtg ctcctggctt (cagcaaagat 1020
aacaatagta tcataactag aaaagaatt	t caggaaggtt taaaaatatt t	tttccagga 1080
gtgagtgagt ttggaaagga atccatcct	t tttcattaca cagactgggt a	agatgatcag 1140
agacctgaaa actaccgtga ggccttggg	t gatgttgttg gggattataa t	ttcatatgc 1200
cctgccttgg agttcaccaa gaagttctc	a gaatggggaa ataatgcctt t	ttctactat 1260
tttgaacacc gatcctccaa acttccgtg	g ccagaatgga tgggagtgat q	gcatggctat 1320
gaaattgaat ttgtctttgg tttacctct	g gaaagaagag ataattacac a	aaaagccgag 1380
gaaattttga gtagatccat agtgaaacc	g tgggcaaatt ttgcaaaata t	gggaatcca 1440
aatgagactc agaacaatag cacaagctg	g cctgtcttca aaagcactga a	acaaaaatat 1500
ctaaccttga atacagagtc aacaagaat	a atgacgaaac tacgtgctca a	acaatgtcga 1560

ttct	ggad	cat d	catt	ttt	cc a	aaagt	cctto	g gaa	aatga	acag	gaaa	atati	tga 1	tgaaq	gcagaa	1620
tggg	gagto	gga a	aagca	aggat	ct co	catco	gctgo	g aad	caatt	caca	tgat	cgga	ctg o	gaaaa	aatcaa	1680
ttta	aacga	att a	acact	cagea	aa ga	aaaga	aaagt	t tgt	gtgg	ggtc	tc					1722
<210 <211 <212 <213 <220 <223	0> SI L> LI 2> TY 3> OF 0> FI 3> OT BC	EQ II ENGTH (PE: RGANI EATUH THER CHE a) NO H: 5' PRT ISM: RE: INF(amino	20 74 Art: DRMA DRMA	ific: FION id se	ial : 12. equer	-7 mu nce	ıtant	: (A:	1995,	/F22	7A/S:	287G	/A328	3W/Y332G)
Glu	Aen	Aen	T10	20 T10	T10	<u> </u>	Thr	Lave	Aen	Glv	Lug	Val	Ara	Glv	Mot	
1	Авр	Авр	шe	5	TTe	AIa	1111	цув	10	GIY	цув	vai	AIG	GIY 15	Met	
Asn	Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro	
Tyr	Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser	
Leu	Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys 60	Tyr	Ala	Asn	Ser	
Cys 65	Cya	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80	
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Суз	Leu	Tyr	Leu 95	Asn	
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp	
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr	
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met	
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160	
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln	
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val	
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu	
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser	
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240	
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Суз	Ser	Arg	Glu 255	Asn	
Glu	Thr	Glu	Ile 260	Ile	Гла	Суз	Leu	Arg 265	Asn	Гла	Asp	Pro	Gln 270	Glu	Ile	
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val	
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp	
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320	
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly	

Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Aap	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr
Lys	Leu	Arg 515	Ala	Gln	Gln	Суз	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	Гла
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560
Phe	Asn	Asp	Tyr	Thr 565	Ser	ГЛа	ГÀа	Glu	Ser 570	СЛа	Val	Gly	Leu		
<210 <211 <212 <213 <220 <223	0> SI L> LI 2> TY 3> OF 3> OF 3> OT BC	EQ II ENGTH (PE: RGAN) EATUH THER ChE 1	D NO H: 1: DNA ISM: RE: INF(hucle	21 L25 Art: DRMAT	ific: FION acid	ial : 12- sequ	-7 mu lence	ıtant e foi	: (Al r ami	1995, ino a	/F22' acid	7A/S2 res:	287G, idue:	/A328 3 68-	3W/Y332G • 442
<400)> SI	EQUEI	ICE :	21											
aaca	ataga	atc a	aaagt	ttto	cc aq	ggcti	ccat	gga	atcaç	jaga	tgto	ggaad	200 8	aaaca	actgac
ctca	agtga	aag a	actg	cttat	ca to	ctaa	atgta	a tgg	gatto	cag	caco	ctaaa	acc a	aaaaa	atgcc
tato	Juan	.ya i	ary	atu	ia tų	Jàrđá	Juggi	a ada	antta	atta	yaau	ate	alt r	raact	atada
atac	ata	ecc t	.ageet	attet	t ac	actti	acca	a aga	aaato	ecta	add	ctcca	aaa a	gaaca	atagat
ttat	ttqa	atc a	acad	atta	ac to	cttca	aqtq	a att	caaa	aaa	atai	aqca	adc (cttto	ataa
aato	cctaa	aaa d	atqta	aacto	et ci	ttq	qaqaa	a aqt	tccc	qaq	caq	ettea	aqt 1	zaqco	tqcat
ttgo	ettto	etc (ctgga	aagco	ca ti	catt	gtto	c acc	cagag	jcca	ttci	gcaa	aag 1	zggtt	ceget
aato	gctco	ett g	gggcg	ggtaa	ac at	cctct	ttat	: gaa	agcta	agga	acaç	gaaco	gtt	gaact	taget
aaat	tgad	etg g	gttgo	ctcta	ag ag	gagaa	atgag	g act	gaaa	ataa	tcaa	agtgt	cct 1	cagaa	ataaa
gato	cccca	aag a	aaatt	ctto	et ga	aatga	aagca	a tti	gttg	gtcc	ccta	atggg	gac 1	cect	tgggt

											0011	CIII	ucu			
gtaaac	tttg	gtcc	gacco	gt g	gatgo	gtgat	tt:	cctca	actg	acat	cgeea	aga	catat	tactt	720	
gaactt	ggac	aatti	taaaa	aa aa	accca	agatt	t ttç	ggtgg	ggtg	ttaa	ataaa	aga 1	zgaaq	gggaca	780	
tggttt	ttag	tcggi	tggt	gc to	cctg	getto	c ago	caaa	gata	acaa	atagi	tat (cataa	actaga	840	
aaagaa	tttc	aggaa	aggti	tt aa	aaaat	attt	tt:	cca	ggag	tga	gtgaq	gtt 1	ggaa	aaggaa	900	
tccatc	cttt	ttcai	ttaca	ac ag	gacto	gggta	a gat	gat	caga	gaco	ctgaa	aaa (ctaco	cgtgag	960	
gccttg	ggtg	atgti	tgtt	aa aa	gatta	ataat	t tt	cata	tgcc	ctgo	cctt	gga q	gttca	accaag	1020	
aagttc	tcag	aatg	gggaa	aa ta	aatgo	cctt	t tt	ctaci	tatt	ttga	aacad	ccg a	atcct	ccaaa	1080	
cttccg	tggc	cagaa	atgga	at g	ggagt	gato	g cat	ggci	tatg	aaat	t				1125	
<pre><210> SEQ ID NO 22 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 68-442 <400> SEQUENCE: 22</pre>																
Asn Il	e Asp	Gln	Ser 5	Phe	Pro	Gly	Phe	His 10	Gly	Ser	Glu	Met	Trp 15	Asn		
Pro As	n Thr	Asp 20	Leu	Ser	Glu	Asp	Сув 25	Leu	Tyr	Leu	Asn	Val 30	Trp	Ile		
Pro Al	a Pro 35	Lys	Pro	Lys	Asn	Ala 40	Thr	Val	Leu	Ile	Trp 45	Ile	Tyr	Gly		
Gly Gl	y Phe	Gln	Thr	Gly	Thr 55	Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys		
Phe Le [.] 65	u Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80		
Val Gl	y Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro		
Gly As	n Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln		
Lys As	n Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	Гла	Ser	Val 125	Thr	Leu	Phe		
Gly Gl 13	u Ser 0	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro		
Gly Se 145	r His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Ala 160		
Asn Al	a Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr		
Leu As:	n Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu		
Ile Il	e Lys 195	Суз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn		
Glu Al 21	a Phe 0	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly		
Pro Th 225	r Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240		
Glu Le	u Gly	Gln	Phe 245	ГЛЗ	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys		
Aap Gl	u Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys		
Asp As	n Asn	Ser	Ile	Ile	Thr	Arg	Lys	Glu	Phe	Gln	Glu	Gly	Leu	Lys		

-continued

275 280 285 Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 290 295 300 His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 305 310 315 320 Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 325 330 335 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 340 345 350 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 355 360 365 Val Met His Gly Tyr Glu Ile 370 375 <210> SEQ ID NO 23 <211> LENGTH: 966 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 117-438 <400> SEQUENCE: 23 ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 qaaaqttccq qaqcaqcttc aqttaqcctq catttqcttt ctcctqqaaq ccattcattq 300 ttcaccagag ccattetgca aagtggttee getaatgete ettgggeggt aacatetett 360 tatgaaqcta qqaacaqaac qttgaactta qctaaattga ctqqttqctc tagaqaqaat 420 qaqactqaaa taatcaaqtq tcttaqaaat aaaqatcccc aaqaaattct tctqaatqaa 480 gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540 gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660 ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaaata 720 ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 atgcat 966 <210> SEQ ID NO 24 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438 <400> SEQUENCE: 24 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 10 5 15

-continued

Leu	Ala	Arg	Val 20	Glu	Arg	Val	Ile	Val 25	Val	Ser	Met	Asn	Tyr 30	Arg	Val
Gly	Ala	Leu 35	Gly	Phe	Leu	Ala	Leu 40	Pro	Gly	Asn	Pro	Glu 45	Ala	Pro	Gly
Asn	Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Гла
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Ala	Asn
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu
Asn	Leu 130	Ala	Lys	Leu	Thr	Gly 135	Суз	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile
Ile 145	Lys	Суз	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Gly	Val	Asn	Phe	Gly 175	Pro
Thr	Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu
Leu	Gly	Gln 195	Phe	LÀa	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp
Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Сув	Pro 285	Ala	Leu	Glu
Phe	Thr 290	Lys	Lys	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320
Met	His														
<210 <211 <212 <213 <220 <223	<pre><210> SEQ ID NO 25 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BCbe puclaid adid seguence</pre>														
<400)> SI	EQUEI	ICE :	25											
gaag	gatga	aca t	cata	aatto	gc aa	acaaa	agaat	gga	aaag	gtca	gago	ggato	gaa d	cttga	acagtt
tttç	ggtgg	gca d	ggta	aacaq	gc ct	ttct	tgga	a att	ccct	atg	caca	ageea	acc t	ctto	ggtaga
ctto	cgatt	ca a	aaaq	gecad	ca gt	ctct	gaco	aag	gtggt	ctg	atat	ttg	yaa t	geea	acaaaa
ator	Juaaa	aut (aaa	agto	la ga	acat	agat	, caa	agtt		cago	JUTTO	oda t	-ygat	attoca
acyı	-99ac		aaa	acit	ja CC	lucaç	Juyac	. yat	Jugul	lal	acci	aaal	-yr d	argge	illea

-continued

gcacctaaac	caaaaaatgc	cactgtattg	atatggattt	atggtggtgg	ttttcaaact 360								
ggaacatcat	ctttacatgt	ttatgatggc	aagtttctgg	ctcgggttga	aagagttatt 420								
gtagtgtcaa	tgaactatag	ggtgggtgcc	ctaggattct	tagetttgee	aggaaatcct 480								
gaggetecag	ggaacatggg	tttatttgat	caacagttgg	ctcttcagtg	ggttcaaaaa 540								
aatatagcag	cctttggtgg	aaatcctaaa	agtgtaactc	tctttggaga	aagttccgga 600								
gcagcttcag	ttagcctgca	tttgctttct	cctggaagcc	attcattgtt	caccagagcc 660								
attctgcaaa	gtggttccgc	taatgctcct	tgggcggtaa	catctcttta	tgaagctagg 720								
aacagaacgt	tgaacttagc	taaattgact	ggttgctcta	gagagaatga	gactgaaata 780								
atcaagtgtc	ttagaaataa	agatececaa	gaaattcttc	tgaatgaagc	atttgttgtc 840								
ccctatggga	ctcctttggg	tgtaaacttt	ggtccgaccg	tggatggtga	ttttctcact 900								
gacatgccag	acatattact	tgaacttgga	caatttaaaa	aaacccagat	tttggtgggt 960								
gttaataaag	atgaagggac	atggttttta	gtctatggtg	ctcctggctt	cagcaaagat 1020								
aacaatagta	tcataactag	aaaagaattt	caggaaggtt	taaaaatatt	ttttccagga 1080								
gtgagtgagt	ttggaaagga	atccatcctt	tttcattaca	cagactgggt	agatgatcag 1140								
agacctgaaa	actaccgtga	ggccttgggt	gatgttgttg	gggattataa	tttcatatgc 1200								
cctgccttgg	agttcaccaa	gaagttetea	gaatggggaa	ataatgcctt	tttctactat 1260								
tttgaacacc	gateeteeaa	acttccgtgg	ccagaatgga	tgggagtgat	gcatggctat 1320								
gacattgaat	ttgtctttgg	tttacctctg	gaaagaagag	ataattacac	aaaagccgag 1380								
gaaattttga	gtagatccat	agtgaaacgg	tgggcaaatt	ttgcaaaata	tgggaatcca 1440								
aatgagactc	agaacaatag	cacaagctgg	cctgtcttca	aaagcactga	acaaaaatat 1500								
ctaaccttga	atacagagtc	aacaagaata	atgacgaaac	tacgtgctca	acaatgtcga 1560								
ttctggacat	cattttttcc	aaaagtettg	gaaatgacag	gaaatattga	tgaagcagaa 1620								
tgggagtgga	aagcaggatt	ccatcgctgg	aacaattaca	tgatggactg	gaaaaatcaa 1680								
tttaacgatt	acactagcaa	gaaagaaagt	tgtgtgggtc	tc	1722								
<210> SEQ <211> LENG <212> TYPE <213> ORGA <220> FEAT <223> OTHE BChe	<pre><210> SEQ ID NO 26 <211> LENGTH: 574 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChe amino acid sequence</pre>												
<400> SEQU	ENCE: 26												
Glu Asp As 1	p Ile Ile I 5	le Ala Thr	Lys Asn Gly 10	Lys Val Arg	g Gly Met 15								
Asn Leu Th	r Val Phe G 20	ly Gly Thr	Val Thr Ala 25	Phe Leu Gly 30	7 Ile Pro								
Tyr Ala Gl 35	n Pro Pro L	eu Gly Arg 40	Leu Arg Phe	Lys Lys Pro 45	Gln Ser								
Leu Thr Ly 50	s Trp Ser A	sp Ile Trp 55	Asn Ala Thr	Lys Tyr Ala 60	a Asn Ser								
Cys Cys Gl 65	n Asn Ile A 7	sp Gln Ser 0	Phe Pro Gly 75	Phe His Gly	/ Ser Glu 80								
Met Trp As	n Pro Asn T 85	hr Asp Leu	Ser Glu Asp 90	Cys Leu Tyr	Leu Asn 95								
Val Trp Il	e Pro Ala P	ro Lys Pro	Lys Asn Ala	Thr Val Leu	l Ile Trp								

-continued

			100					105					110		
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr
Aap	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Сүз	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	Lys	Суз	Leu	Arg 265	Asn	ГÀа	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Tyr	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	ГÀа	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Asp	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr
Lys	Leu	Arg 515	Ala	Gln	Gln	Cys	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys

-continued

Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 535 540 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 555 550 560 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570 <210> SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 27 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360 aatcotaaaa gtgtaactot otttggagaa agttooggag cagottoagt tagootgoat 420 ttgetttete etggaageea tteattgtte accagageea ttetgeaaag tggtteeget 480 aatgeteett gegeggtaac atetettat gaagetagga acagaacgtt gaaettaget 540 aaattqactq qttqctctaq aqaqaatqaq actqaaataa tcaaqtqtct taqaaataaa 600 gatececeaag aaattettet gaatgaagea tttgttgtee eetatgggae teetttgggt 660 720 gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 780 gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca tggtttttag tctatggtgc tcctggcttc agcaaagata acaatagtat cataactaga 840 aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900 tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960 gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020 aagtteteag aatggggaaa taatgeettt ttetaetatt ttgaacaeeg ateeteeaaa 1080 cttccgtggc cagaatggat gggagtgatg catggctatg acatt 1125 <210> SEQ ID NO 28 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE amino acid sequence for residues 68-442 <400> SEQUENCE: 28 Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 1 5 10 15 Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 30 Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 35 40 45

-continued

Gly	Gly 50	Phe	Gln	Thr	Gly	Thr 55	Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys
Phe 65	Leu	Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80
Val	Gly	Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln
ГÀа	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	Lys	Ser	Val 125	Thr	Leu	Phe
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Ala 160
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr
Leu	Asn	Leu	Ala 180	ГЛЗ	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu
Ile	Ile	Lys 195	Суз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Aab	Met 235	Pro	Asp	Ile	Leu	Leu 240
Glu	Leu	Gly	Gln	Phe 245	Lys	Гла	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Tyr 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Asp	Tyr	Asn 330	Phe	Ile	Сүз	Pro	Ala 335	Leu
Glu	Phe	Thr	Lys 340	Lys	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly
Val	Met 370	His	Gly	Tyr	Asp	Ile 375									
<pre><210> SEQ ID NO 29 <211> LENGTH: 975 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid recidues 117 441</pre>															
<400> SEQUENCE: 29															
ggti	ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt														
gaaa	agagt	ta t	tgta	agtgi	cc aa	atga	actat	ago	ggtgg	ggtg	ccct	cagga	att «	cttag	getttg
cca	ygaaa	ALC (rga	Jacr	e ag	ygga	acato	i gat	Lttat	LEEG	acca	acaq	אדב פ	Jacro	utcag

-continued

tggg	yttca	aaa a	aaaat	cataç	gc aq	geett	tggt	gga	aaato	ecta	aaaq	gtgta	aac	tctct	ttgga	. :	240
gaaa	agtto	ccg (gagca	agcti	cc aq	gttag	geete	g cat	ttgo	ttt	ctco	ctgga	aag	ccatt	cattg		300
ttca	accaç	gag (ccatt	cctgo	ca aa	agtgę	gttcc	e get	aato	gctc	cttç	gggcá	ggt	aacat	ctctt		360
tato	gaago	ta	ggaad	cagaa	ac gt	tgaa	actta	a get	aaat	tga	ctg	gttgo	ctc	tagaq	gagaat	4	420
gaga	actga	aaa	taato	caagt	tg to	ettaç	gaaat	: aaa	agato	cccc	aaga	aatt	cct	tctga	aatgaa	. 4	480
gcat	ttgt	tg	tecco	ctato	aa a	actco	etttg	g ggt	gtaa	act	ttg	gtcc	gac	cgtg	gatggt	í	540
gatt	ttct	ca (ctgad	catgo	cc aç	gacat	atta	a ctt	gaad	ttg	gaca	aatti	caa	aaaaa	acccag		600
attt	tggt	gg g	gtgtt	taata	aa aq	gatga	aaggg	g aca	atggt	ttt	tagi	cctat	gg	tgcto	cctggc	(660
ttca	igcaa	aag	ataad	caata	ag ta	atcat	caact	aga	aaaq	gaat	ttca	aggaa	agg	tttaa	aaata		720
ttt	ttco	ag g	gagto	gagto	ga gt	ttg	gaaag	g gaa	atcca	atcc	ttt	tcat	ta	cacaç	gactgg		780
gtag	gatga	atc a	agaga	accto	ga aa	aacta	accgt	: gag	ggcct	tgg	gtga	atgti	gt	tgggg	gattat	8	340
aatt	tcat	at g	geeet	geet	t g	gagti	caco	c aag	gaagt	tct	caga	aatgo	333	aaata	aatgcc	9	900
ttt	tcta	act a	attt	gaa	ca co	gato	cctcc	c aaa	actto	cgt	ggco	cagaa	atg	gatg	ggagtg		960
atgo	atgo	gct a	atgad	2												9	975
<210 <211 <212 <213 <220 <223	<210> SEQ ID NO 30 <211> LENGTH: 325 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE amino acid sequence for residues 117-441																
<400	<400> SEQUENCE: 30																
Gly 1	Phe	Gln	Thr	Gly 5	Thr	Ser	Ser	Leu	His 10	Val	Tyr	Asp	Gly	Lys 15	Phe		
Leu	Ala	Arg	Val 20	Glu	Arg	Val	Ile	Val 25	Val	Ser	Met	Asn	Tyr 30	Arg	Val		
Gly	Ala	Leu 35	Gly	Phe	Leu	Ala	Leu 40	Pro	Gly	Asn	Pro	Glu 45	Ala	Pro	Gly		
Asn	Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Lys		
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80		
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly		
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Ala	Asn		
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu		
Asn	Leu 130	Ala	Lys	Leu	Thr	Gly 135	Суз	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile		
Ile 145	Lys	СЛа	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160		
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Gly	Val	Asn	Phe	Gly 175	Pro		
Thr	Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu		
Leu	Gly	Gln 195	Phe	Lys	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp		

Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Tyr	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Сүв	Pro 285	Ala	Leu	Glu
Phe	Thr 290	Lys	Гла	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320
Met	His	Gly	Tyr	Asp 325											

The invention claimed is:

1. A butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 8, 14, and 26.

2. A pharmaceutical composition comprising:

a butyrylcholinesterase variant peptide comprising an 30 amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 8, 14, and 26; and

a suitable pharmaceutical carrier.

3. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of

a butyrylcholinesterase variant polypeptide of claim 1 to lower blood cocaine concentration.

4. The method of claim **3**, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to butyrylcholinesterase.

5. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of a BChE butyrylcholinesterase pharmaceutical composition of claim **2** to lower blood cocaine concentration.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

 PATENT NO.
 : 7,731,957 B1

 APPLICATION NO.
 : 12/192394

 DATED
 : June 8, 2010

 INVENTOR(S)
 : Zhan et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 99, line 25-27 should read

What is claimed is:

1. A butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO 14.

Column 99 lines 28-33 should read

2. A pharmaceutical composition comprising: a butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO 14 and a suitable pharmaceutical carrier.

Column 99 lines 34-35 - Column 100 lines 1-2 should read

3. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of the butyrylcholinesterase variant polypeptide of claim 1 to lowering blood cocaine concentration.

Column 100 lines 3-4 should read

4. The method of claim 3, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to wild-type butyrylcholinesterase.

Column 100 lines 5-8 should read

5. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of the BChE butyrylcholinesterase pharmaceutical composition of claim 2 to lower blood cocaine concentration.

Signed and Sealed this Fourth Day of January, 2011

Jand J.

David J. Kappos Director of the United States Patent and Trademark Office